ĐĎॹá>ţ˙ žŔţ˙˙˙şťź˝˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙ěĽÁ€đżăÁbjbjëČëČ.Ή˘‰˘/Í˙˙˙˙˙˙ˇ€€€€€˙˙˙˙””””Ź@”ş|ňT:ŽŽŽŽi "‹ — {Ÿ{Ÿ{Ÿ{Ÿ{Ÿ{Ÿ{Ź~˘NbŸ{Հ<&i i <&<&Ÿ{€€ŽŽŰt|fDfDfD<&€Ž€Ž{fD<&{fDfD˛ !ZČi{Ž˙˙˙˙ŕ@MőđĘ”N<śéhô‰{Š|0ş|ÝiŒ°Bb°Üi{°€i{ Ÿ Hç!ęfDŃ"ź#ŻŸ Ÿ Ÿ Ÿ{Ÿ{fDŸ Ÿ Ÿ ş|<&<&<&<&˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙°Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ ( F:Asthma 1. Factors that can contribute to asthma or airway hyperreactivity may include any of the following: Chronic sinusitis or rhinitis Aspirin or nonsteroidal anti-inflammatory drug hypersensitivity Use of beta-adrenergic receptor blockers All of above 2. Mechanism of bronchoconstriction during asthma attack includes all, except: mucus plugs airway spasm proliferation swollen middle layer 3. Which statement about asthma is wrong? Asthma is a chronic inflammatory disorder of the airways Airway obstruction is often caused by abnormal sensitivity of cholinergic and peptidergic receptors In asthma, airway obstruction is irreversible Cigarette smoke, cold air, and viral infections can provoke asthma attacks 4. Step 1 – Intermittent asthma is characterized by all except: Intermittent symptoms occurring less than once a week Nocturnal symptoms occurring less than twice a week Asymptomatic with normal lung function between exacerbations FEV1 or PEF rate greater than 80%, with less than 20% variability 5. Step 2 - Mild persistent asthma is characterized by all except: Symptoms occurring more than once a week but less than once a day Nocturnal symptoms occurring more than twice a month Brief exacerbations FEV1 or PEF rate greater than 80% predicted, with variability of 20-30% 6. Step 3 - Moderate persistent asthma is characterized by all except: Weekly symptoms Exacerbations affect activity and sleep Nocturnal symptoms occurring more than once a week FEV1 or PEF rate 60-80% of predicted, with variability greater than 30% 7. Step 4 - Severe persistent asthma is characterized by all except: Symptoms occurring more than once a week but less than once a day Frequent exacerbations Frequent nocturnal asthma symptoms FEV1 or PEF rate less than 60%, with variability greater than 30% 8. A diagnosis of asthma can be confirmed using all investigation, except: Spirometry tests Skin testing A chest x-ray Exhaled nitric oxide (NO) 9. Symptoms of asthma may include the following: Chest tightness Sputum production Decreased exercise tolerance All of above 10. . Pharmacologic treatment of Intermittent asthma include: long-term oral corticosteroid therapy The controller medication is an inhaled corticosteroid (800-2000 mcg) The controller medication is an inhaled corticosteroid (200-500 mcg) A controller medication is not needed 11. Pharmacologic treatment of Mild persistent asthma include: The controller medication is an inhaled corticosteroid (200-500 mcg), cromolyn, nedocromil, or a leukotriene antagonist The controller medication is an inhaled corticosteroid (800-2000 mcg) A controller medication is not needed Long-term oral corticosteroid therapy 12. Pharmacologic treatment of Moderate persistent asthma include: The controller medication is an inhaled corticosteroid (200-500 mcg), cromolyn, nedocromil, or a leukotriene antagonist The controller medication is an inhaled corticosteroid (800-2000 mcg) and a long-acting bronchodilator (either beta-agonist or sustained-release theophylline) The controller medication is an inhaled corticosteroid (800-2000 mcg), a long-acting bronchodilator (beta-agonist and/or theophylline), and long-term oral corticosteroid therapy Long-term oral corticosteroid therapy 13. Pharmacologic treatment of Severe persistent asthma include: The controller medication is an inhaled corticosteroid (500-1000 mcg) The controller medication is an inhaled corticosteroid (800-2000 mcg) The controller medication is an inhaled corticosteroid (800-2000 mcg), a long-acting bronchodilator (beta-agonist and/or theophylline), and long-term oral corticosteroid therapy The controller medication is an inhaled corticosteroid (200-500 mcg) and a long-acting bronchodilator (either beta-agonist or sustained-release theophylline) 14. The short-acting Beta-adrenergic agonists is: Salmeterol Albuterol Theophylline Ipratropium 15. The long-acting Beta-adrenergic agonists is: Salmeterol Ventolin Cromolyn Ipratropium 16. Mast cell stabilizer is: Beclomethasone Ventolin Cromolyn Ipratropium 17. Corticosteroid is: Fluticasone Salmeterol Cromolyn Ipratropium 18. Complications associated with long-term corticosteroid used for asthma may include: Osteoporosis Immunosuppression Weight gain All of above COPD 1. Risk factors for COPD include: Cigarette smoking Lung infections Exposure to pollutants All the Answers 2. Which statement about COPD is not true? a chronic, slowly progressive disorder characterised by airways obstruction (FEV1 < 80% predicted and FEV1/FVC ratio < 70%) COPD is an important cause of activity limitation in the population obstructive syndrome is completely reversible by bronchodilator The first symptoms of chronic bronchitis are cough and mucus production 3. Mild COPD is characterized by: airflow limitation (FEV1/FVC < 0.70; 50% < FEV1 < 70% predicted) airflow limitation (FEV1/FVC < 0.70; FEV1 70% predicted) airflow limitation (FEV1/FVC < 0.70; 30% < FEV1 < 60% predicted) airflow limitation (FEV1/FVC < 0.70; FEV1 80% predicted) 4. Moderate COPD is characterized by: airflow limitation (FEV1/FVC < 0.70; 50% < FEV1 < 80% predicted) airflow limitation (FEV1/FVC < 0.70; FEV1 . 80% predicted) airflow limitation (FEV1/FVC < 0.70; 30% < FEV1 < 60% predicted) airflow limitation (FEV1/FVC < 0.70; FEV1 < 40% predicted ) 5. Severe COPD is characterized by: airflow limitation (FEV1/FVC < 0.70; 50% < FEV1 < 80% predicted) airflow limitation (FEV1/FVC < 0.70; 40% < FEV1 < 60% predicted) airflow limitation (FEV1/FVC < 0.70; 30% < FEV1 < 50% predicted) airflow limitation (FEV1/FVC < 0.70; FEV1 . 80% predicted) 6. Very Severe COPD is characterized by: airflow limitation (FEV1/FVC < 0.70; 30% < FEV1 < 50% predicted) airflow limitation (FEV1/FVC < 0.70; FEV1 < 40% predicted airflow limitation (FEV1/FVC < 0.70; FEV1 < 30% predicted airflow limitation (FEV1/FVC < 0.70; FEV1 < 50% predicted 7. Complications of COPD include: Pulmonary bullae pneumothorax Respiratory failure All the Answers 8. The physical sighs of Emphysema are all, except: decrease vesicular breath tympanic sound dullness on percussion shortness of breath on exertion 9. Management of Stable COPD includes: Smoking Cessation Pharmacological Therapy Long-Term Oxygen Therapy All the Answers 10. The Management of Mild COPD includes: Smoking Cessation oxygen therapy corticosteroids long-time bronchodilator 11. The Management of Severe COPD includes: Smoking Cessation oxygen therapy corticosteroids All the Answers 12. A diagnosis of COPD can be confirmed using all investigation, except: Pulmonary function test Skin testing A chest x-ray Blood gas levels Pneumonia 1. Wich of the following organisms should be suspected in patients with community-acquired pneumonia: mycobacterium tuberculosis histoplasma capsulatum p.carinii Steptococcus 2. Nosocomial pneumonia is: Tuberculosis in a a patient suffering from AIDS infection of a nasal cavity in immuno compromised patient. Hospital acquired pneumonia A type of community acquired pneumonia 3. Which of the following condition predispose to Aspiration pneumonia ? head trauma all the answers altered conciousness cerebrovascular accident 4. Wich of the following organisms should be suspected in an immunocompromised patient which shows diffused infiltrates on the chest Xray? p.carinii legionalle herpes zoster virus All the Answers 5. Which of the following condition predispose to pneumonia in immuno compromised patients? head trauma all the answers AIDS cerebrovascular accident 6. Risk factors for Hospital-acquired pneumonia? mechanical ventilation, prolonged malnutrition, underlying heart and lung diseases All the Answers 7. Which is the most common cause of hospital-acquired pneumonia? str.pneumonVae All the Answers S. aureus malignancy 8. Wich of the following organisms should be suspected in patient whith homogeneous opacity localised to the one lobe on the chest Xray? p.carinii str.pneumonVae herpes zoster virus All the Answers 9. Which is the most common cause for a focal lesion on a chest x ray? benign lesion All the Answers bacterial infection. malignancy 10. Pneumatoceles is a feature of pneumonia due to: H. influenza E. coli S. aureus Abscess formation 11. Complications of pneumonia includes: Respiratory and circulatory failure acute respiratory distress syndrome pleural effusion All the Answers 12. Complications of pneumonia includes all except: septic shock lung abscess sepsis rheumatoid arthritis 13. Drug of choice in mycoplasma pneumonia streptomycin tetracycline erythromycin moxalactam 14. Drug of choice in patient with I gr. of Community-acquired pneumonia is: streptomycin tetracycline Trimethoprim-sulfamethoxazole amoxicillin 15. Drug of choice in patient with II gr. of Community-acquired pneumonia is: tetracycline erythromycin cefuroxim Trimethoprim-sulfamethoxazole Lung abscesses and bronchiectasis 1. Bronchiectasis associated with tuberculosis is usually called dry bronchiectasis and is seen most commonly in the: Lower lobes Upper lobes Middle lobes all the answers 2. The diagnostic modality of choice for demonstrating or ruling out bronchiectasis is: Chest radiography High-resolution computed tomography Bronchography Results of sputum culture 3. The first generation cephalosporins include: cefaclor, cefamandole cefazolin cefixime 4. The second generation cephalosporins include: cefaclor cefadroxil cefoperazone, cefotaxime 5. The third generation cephalosporins include: cefaclor cefadroxil cefoperazone cephalothin 6. The fourth generation cephalosporins include: cefaclor, cefamandole cefepime cefixime 7. Fluoroquinolones include all, except: ciprofloxacin cefquinome levofloxacin lomefloxacin 8. Macrolide antibiotics are all, except: erythromycin, clarithromycin, doxycycline, roxithromycin 9. Which of the following is/are a cause of acquired bronchiectasis Marfan syndrome Williams-Campbell syndrome Foreign Body Cystic Fibrosis 10. In a patient with long standing, severe, bronchiectasis and infection, which of the following would be elevated? WBC RBC Hematocrit All the above 11. Mucolytics agents are commonly used to enhance the mobilization of secretions in patients with bronchiectasis. Which of the following is/are classified as a mucolytic agent(s)? Acetylcysteine Cromolyn Sodium Beclomethasone Trimethoprim-sulfamethoxazole 12. Which of the following is a cause of acquired bronchiectasis Marfan syndrome Young syndrome bronchopulmonary aspergillosis Cystic Fibrosis 13. The treatment bronchiectasis includes: Antibiotics Surgical Care Bronchodilators All of the above Pleuritis 1. The causes of pleural transudates are all except: Congestive heart failure Cirrhosis (hepatic hydrothorax) Atelectasis (which may be due to malignancy or pulmonary embolism) Parapneumonic causes 2. The causes of pleural transudates are all except: Hypoalbuminemia Asbestos exposure   Nephrotic syndrome 4. Peritoneal dialysis 3. The causes of pleural exudates are all except: Congestive heart failure Malignancy (carcinoma, lymphoma, mesothelioma) Pulmonary embolism Collagen-vascular conditions (rheumatoid arthritis, lupus) 4. The causes of pleural exudates are all except: Myxedema Trauma Postcardiac injury syndrome Esophageal perforation 5. The clinical picture of pleuritis may include: Pleuritic chest pain, Vague discomfort Sharp pain that worsens on inspiration All of above 6. The clinical picture of pleuritis may include all except: Dyspnea A pleural friction rub Absent tactile fremitus Bronchial sound above dulness 7. Which of the following investigations would be of greatest use in establishing a diagnosis of pleural effusion? Lateral chest X-ray Serum rheumatoid factor, anti-nuclear factor and anti-DNA antibodies Pleural aspiration Arterial blood gas 8. Light's criteria of Exudative Pleural Effusions include all except: Fluid LDH* e" 2/3 ULN for serum LDH Fluid total protein e" 3 g/dL Fluid cholesterol e" 80 mg/dL Pleural fluid: serum total protein ratio e" 0.5 9. Light's criteria of Exudative Pleural Effusions include all except: Fluid LDH* e" 2/3 ULN for serum LDH Fluid total protein e" 5 g/dL Fluid cholesterol e" 60 mg/dL Pleural fluid: serum total protein ratio e" 0.5 10. Light's criteria of Exudative Pleural Effusions include all except: 1. Fluid LDH* e" 2/3 ULN for serum LDH 2. Fluid total protein < 3 g/dL 3. Fluid cholesterol e" 60 mg/dL 4. Pleural fluid: serum total protein ratio e" 0.5 Anemia 1. In Ukraine normal Hb concentration for men is: A. 120-140 g/L B. 140-160 g/L C. 150-170g/L D. 160-180 g/L 2. Which anemia is Macrocytic: A. Aplastic anemia B. Anaemia of chronic disease C. Vitamin B12 deficiency D. Iron deficiency 3. The signs of Sideropenic syndrome include all, except: A. concave nails (koilonychias) B. cheilosis, angular stomatitis C. altered taste D. dyspnea 4. The iron transporting protein, which can transport iron from cells (intestinal, macrophages) to specific receptors on erythroblasts and liver cells, is: A. hemosiderin B. transferrin C. ferritin D. all of above 5. Laboratory Studies in diagnostic of iron deficiency: A. low serum iron and ferritin with an elevated total iron-binding capacity B. low serum iron and high ferritin with an decreased total iron-binding capacity C. high serum iron and ferritin with an elevated total iron-binding capacity D. low serum iron and ferritin with an decreased total iron-binding capacity 6. The most common causes of megaloblastic anemias are, exclude: A. iron deficiency B. disturbances in folic acid metabolism C. folic acid deficiency D. deficiency of vitamin B12 7. Neurological symptoms of Vitamin B12 deficiency megaloblastic anemias include: A. loss of proprioception B. Optic atrophy - blindness C. Glove and stocking paraesthesiae all of above 8. Blood film of megaloblastic anemia exclude: A. neutrophil hypersegmentation B. oval macrocytosis C. hypochromic red cells D. decreased reticulocyte count 9. The most dangerous side effect of parenteral use of iron-carbohydrate complexes is: A. anaphylactic reactions B. dyspepsia C. constipation D. all of above 10. Pica chlorotica is characterized by: A. altered taste B. dry, hyperemic or “geographic” tongue C. sparse hair, falling out D. concave nails (koilonychias) 11. The most important storage pool of iron is: A. Transferrin B. hemosiderin ferritin myoglobin 12. Drugs that can cause megaloblastic anemia are, except: A. Amyodarone B. 6-Mercaptopurine C. Methotrexate D. 5-Fluorouracil, 5-azacytidine 13. Anaemic (hypoxic) Syndrome exclude: A. Fatigue, weakness B. Bradycardia C. Dyspnea D. Dizziness 14. Hemolysis produce: Unconjugated (indirect) hyperbilirubinemia Decrease LDH serum levels C. Direct bilirubinemia D. Discolored, acholic stool 15. The signs of hemolytic anemia include all, except: A. Jaundice B. Gallstones C. Altered taste D. General pallor 16. The direct Coombs' test is used to detect: A. IgG antibodies against RBCs in a patient's serum B. RBC-binding antibody IgG is present on RBC membranes of patient C. IgG antibodies against complement D. Deficiency of IgG antibodies in a patient's serum 17. Specific treatment for Hereditary spherocytosis is: A. azathioprine B. splenectomy C. cyclophosphamide D. prednisolone 18. Vaso-occlusive crisis are typical sign of: A. Sickle Cell Anemia B. Thalassaemia C. Hereditary spherocytosis D. Autoimmune haemolytic anaemia 19. Target cells are the most specific for: A. Sickle Cell Anemia B. Thalassaemia C. Acquired aplastic anemia D. Autoimmune haemolytic anaemia 20. The drug for the treatment of Sickle Cell Anemia is: A. Hydroxyurea B. azathioprine C. prednisolone D. cyclophosphamide 21. The most common syndromes in patients with aplastic anemia are all, except: A. Hepatosplenomegaly B. Recurrent infections C. Anemia D. Haemorrhagic syndrome 22. Bone marrow biopsy in middle-aged individuals with aplastic anemia is: >30% cellular <50% cellular <30% cellular D. <20% cellular 23. The criteria of the International Aplastic Anemia Study Group includes: A. Neutrophils < 1 x 109/L Platelets < 100 x 109/L B. Neutrophils < 1 x 109/L Platelets < 20 x 109/L C. Neutrophils < 0.5 x 109/L Platelets < 20 x 109/L D. Neutrophils < 0.5 x 109/L Platelets < 10 x 109/L 24. The criteria of the International Aplastic Anemia Study Group includes: A. Neutrophils < 1 x 109/L Platelets < 20 x 109/L B. Neutrophils < 0.1 x 109/L Reticulocytes < 10 x 109/L C. Neutrophils < 0.5 x 109/L Reticulocytes < 2 x 109/L D. Neutrophils < 0.5 x 109/L Reticulocytes < 1 x 109/L Acute leukemias 1. The most common symptoms of Acute leukemias are: fever, malaise, weight loss petechiae, easy bruising, epistaxis, C. pallor, fatigue, tachycardia D. all of above 2. Symptoms of bone marrow failure in patients with Acute leukemias include all, except: bone pain multiple eccymoses C. fatigue D. fever 3. Specific sign in CBC and peripheral smear in patients with Acute leukemias: A. pancytopenia B. high WBC count C. peripheral blasts cells D. high platelets 4. Symptoms of organ infiltration with leukemic cells in patients with Acute leukemias include all, except: A. splenomegaly B.  HYPERLINK "http://emedicine.medscape.com/article/175667-overview" bone pain  C. bleeding D. gingivitis 5. Leukostasis is: leukemic gap palpable lymphadenopathy C. respiratory distress and altered mental status due to markedly elevated WBC counts D. gingivitis due to neutropenia with swollen gums 6. CBC count with Peripheral blood smear in Acute Myeloid Leukemia don’t show: A. circulating blasts B. anaemia with a normal or raised MCV C. leukemic gap D. increase of different midstage progenitor cells 7. Induction therapy of Acute Myeloid Leukemia "3 and 7" include: A. Vincristine B. Daunorubicin C. Azathioprine D. Methotrexate 8. Chemotherapy for Acute Lymphoid Leukemia include phases: A. Consolidation B. Remission induction C. CNS prophylaxis D. all of above 9. Induction therapy of ALL - 5-drug regimen - doesn’t include: A. L -asparaginase B. Mercaptopurine C. Vincristine D. Prednisone 10. Small, punctate, hemorrhagic rashes that are not palpable are: A. petechiae B. ecchymoses C. purpura D. all of above 11. AML is defined as the presence in the bone marrow of: A. different midstage progenitor cells B. < 20% blasts C. > 20% blasts D. > 50% blasts 12. CNS prophylaxis and treatment of ALL doesn’t include: A. intrathecal methotrexate B. corticosteroids C. IV vincristine D. cytosine arabinoside 13. Induction therapy of ALL - 4-drug regimen - doesn’t include: A. Vincristine B. Cyclophosphamide C. Azathioprine D. Methotrexate 14. Leukemic gap is: A. severe leukocytopenia with blast cells in the peripheral blood B. blast cells with absence of different midstage progenitor cells (myelocytes, metamyelocytes) in the peripheral blood C. very low blast cells count in the peripheral blood comparatively with bone marrow D. all of above Chronic leukemias 1. Philadelphia (Ph) chromosome is the most common find in patients with: A. Chronic lymphoid leukaemia B. Polycythaemia rubra vera C. Chronic myeloid leukaemia D. Myelofibrosis 2. Chronic myeloid leukemia is characterized by: increased number of granulocytes and their immature precursors decrease of different midstage progenitor cells C. increased number of granulocytes with leukemic gap D. circulating blasts 3. Signs of chronic lymphocytic leukemia include, except: splenomegaly asymptomatic lymphadenopathy C. autoimmune hemolytic anemia D. plethora 4. According to the Binet staging system of Chronic lymphocytic leukemia: Absolute lymphocytosis of > 10,000/źL in blood and e" 30% lymphocytes in bone marrow, Hb e" 10 g/dL; Platelets e" 100,000/źL with 3-5 involved sites of lymphoid enlargement is: A. Stage A  B. Stage B C. Stage C D. Stage III 5. Acute phase, or blast crisis of Chronic myeloid leukaemia is characterized by: A. peripheral blood blasts of 10% B. peripheral blood blasts of 20% C. peripheral blood blasts of 30% D. peripheral blood blasts of 50% 6. CBC count with peripheral blood smear in patients with Chronic myeloid leukaemia isn’t characterized by: A. absolute eosinophilia and basophilia B. presence of the different midstage progenitor cells C. leukemic gap D. myeloblasts 7. The first-line therapy in chronic phase Chronic myeloid leukaemia is: A. Hydroxyurea B. Busulfan C. Vincristine D. Imatinib 8. Initial therapy of CLL include: cyclophosphamide chlorambucil C. rituximab D. all of above 9. Symptoms of Polycythemia vera don’t include: A. Plethora B. Pruritus C. Pallor D. Splenomegaly 10. Criteria for Diagnosis of Polycythemia Vera include, except: A. Splenomegaly B. Enlarged megakaryocytes C. Panmyelosis D. Plethora 11. Chronic lymphocytic leukemia is a monoclonal disorder, which is characterized by: progressive accumulation of functionally competent B-lymphocytes progressive accumulation of functionally incompetent nonproliferative lymphocytes progressive accumulation of T-lymphocytes with increase immunoglobulin production progressive accumulation of lymphocytes precursor 12. Chronic lymphocytic leukemia hallmark don’t include: A. sustained, absolute peripheral mature lymphocytosis > 5 × 109/l B. autoimmune hemolytic anemia increased lymphocytes (> 30%) in the bone marrow signs duration > 3 months 13. According to the Rai-Sawitsky staging system of Chronic lymphocytic leukemia: Absolute lymphocytosis of > 10,000/źL in blood and e" 30% lymphocytes in bone marrow plus hepatomegaly or splenomegaly is: A. Stage 0 B. Stage I C. Stage II D. Stage IV 14. Complete cytogenetic response in patients with Chronic myeloid leukaemia is produced by: A. Busulfan B. Imatinib C. Vincristine D. Cytosine arabinoside 15. Criteria for Diagnosis of Polycythemia Vera include: A. Erythrocytosis B. Platelet count < 400,000 źL asymptomatic lymphadenopathy Plasma erythropoietin level < 4 mUnits/mL Lymphomas, Multiple myeloma 1. Multiple myeloma is a malignant proliferation of: functionally competent B-lymphocytes atypical megakaryocytes C. atypical plasma cells that produce monoclonal immunoglobulin D. typical plasma cells that produce polyclonal immunoglobulin 2. The most common organ involvement of Multiple myeloma include, except: kidney bone C. bone marrow D. gastrointestinal system 3. The most common Laboratory Studies result of Multiple myeloma is high: RBC WBC C. HYPERLINK "http://emedicine.medscape.com/article/201066-overview"  platelet counts  D. ESR 4. Bence Jones protein is: A. free monoclonal ş or ť light chains in the urine B. heavy chains ł or ą in the serum C. monoclonal immunoglobulin in the serum D. polyclonal immunoglobulin 5. In patients without serum M protein, myeloma is indicated by, except: A. absolute peripheral lymphocytosis > 5 × 109/l B. Bence Jones proteinuria > 300 mg/24 h C. osteolytic lesions D. sheets or clusters of marrow plasma cells 6 According to the Salmon-Durie staging system for multiple myeloma: Calcium level > 2,75 mM/L, X-ray showing advanced lytic bone disease, Plasma cell in bone marrow > 60% of nuclear cells is: A. Stage I B. Stage II C. Stage III D. Stage IV 7 The most appropriate treatment of Skeletal lesions in patient with Multiple myeloma is: A. Allopurinol B. phluossen C. vit. D3 D. bisphosphonate 8 "B symptoms" in patient with Hodgkin lymphoma include, except: fever night sweats jaundice D. unexplained weight loss 9 The main Symptom of Hodgkin lymphoma is: A. pallor B. painless lymphadenopathy C. bleeding, purpura D. bone pain 10. According to the Ann Arbor classification for Hodgkin lymphoma 2 or more lymph node areas on the same side of the diaphragm is: A. Stage I B. Stage II C. Stage III D. Stage IV 11. A mediastinal mass greater than one third of the intrathoracic diameter (on a chest radiograph) according to the Ann Arbor classification for Hodgkin lymphoma is denoted as: "A" designation "B" designation "E" designation "X" designation 12. Treatment of Hodgkin lymphoma include: A. Chemotherapy B. stem cell transplantation C. Radiation therapy D. all of above 13. According to the Ann Arbor classification for Hodgkin lymphoma the involvement of the spleen is denoted as: "S" designation "B" designation "E" designation "X" designation 14. Pathognomic sign of Hodgkin lymphoma in Biopsy is: A. Bence Jones protein B. Target cells C. Reed-Sternberg cells D. Clusters of plasma cells Platelet and coagulation disorders 1. The most common hereditary coagulation disorder is: A. von Willebrand's disease B. haemophilia C. disseminated intravascular coagulation D. Immune thrombocytopenic purpura 2. Hemophilia A is a congenital deficiency of: A. factor VIII B. factor IX C. factor VIII and IX D. factor V 3. Coagulation factor VIII is: A. Prothrombin B. Christmas factor C. Fibrinogen D. Antihemophilic globulin 4.The most common symptoms of hemophilia are, except: A. recurrent haemarthroses B. prolonged bleeding C. petechiaes D. muscle haematomas 5. In a patient presenting with a bleeding disorder, which of the following clinical features would be most suggestive of a coagulation defect as opposed to a platelet disorder? A) Epistaxis B) Haemarthrosis C) Menorrhagia D) Purpura 6 In hemophilia: A. fibrinogen level is increased B. platelet count are decreased C. prothrombin times is shortened D. activated partial thromboplastin times (aPTTs) is prolonged 7. In Moderate hemophilia factor VIII or IX level is: A. < 1% of normal B. 1 to 5% of normal C. 5 to 25% of normal D. 10 to 50% of normal 8. Long-term Complications of Hemophilia exclude: A. Hepatosplenomegaly B. Arthropathy of large joints C. Atrophy of muscles secondary to haematomas D. Mononeuropathy resulting from pressure by haematomas 9. The best treatment of hemophilia is: A. Fresh frozen plasma B. Replacement of the deficient factor C. desmopressin D. antifibrinolytic drug 10. Petechiae is a result of: A. easy bruising B. bleeding C. extravasation of blood from capillaries into skin and mucous membranes D. muscle hematoma 11. The hallmark of Immune thrombocytopenic purpura is: A. thrombocytopenia, neutropenia B. isolated thrombocytopenia C. thrombocytopenia, anemia D. pancytopenia 12. The symptoms of Immune thrombocytopenic purpura don’t include: A. Widespread petechiae and ecchymoses B. gingival bleeding C. Konchalovsky syndrome D. Haemarthrosis 13. Immune thrombocytopenic purpura may occur due to: A. NSAIDs B. viral upper respiratory infection C. hepatitis virus D. all above 14. Treatment of chronic Immune thrombocytopenic purpura doesn’t includes: A. Splenectomy B. Rituximab, a monoclonal antibody C. Methylprednisolone D. Cephalosporins Gastritis 1. The aetiological factor of gastritis are, except: A. Klebsiella B. non-steroidal anti-inflammotory drugs C. Helicobacter pylori D. smoking 2. Helicobacter pylori produce enzyme: A. lipase B. somatostatin C. lactase D. urease 3. The effects of Helicobacter pylori are, except: A. reduce gastric mucosal resistance B. reduce gastrin release from G cells C. release cytotoxins D. increase acid secretion 4. The production of ammonia from urea by Helicobacter pylori: A. reduce the pH around the bacterium B. raise the pH around the bacterium C. raise gastric mucosal resistance D. reduce acid load to duodenum 5. The best diagnostic test for Helicobacter pylori is: A. histology B. serology C. urea breath test D. rapid urease test 6. Helicobacter pylori exclusively colonises: A. gastric-type epithelium B. intestinal epithelium C. duodenum epithelium D. esophageal epithelium 7. The urea breath test is useful in the diagnosis of which one of the following conditions? Bacterial overgrowth Helicobacter pylori infection Lactose intolerance Coeliac disease 8. For urea breath test are used: A. C14 B. C13 C. J131-hyppuran D. Tc99-sulphur 9. H2-receptors antagonists drugs are used: A. 6-hourly B. 8-hourly C. 12-hourly or at night once weakly 10. H2-receptors antagonists drugs are, except: A. ranitidine B. omeprazole C. cimitidine D. famotidine 11. Misoprostol is: A. H2-receptors antagonists B. syntetic prostaglandin analogues C. antacid D. H+/K+ ATPase inhibitor 12. Autoimmune gastritis is characterized by: A. hyperacidity B. severe pain C. mucus hypertrophy D. hypoacidity 13. The most powerful inhibitors of gastric secretion are: A. antacids B. proton pump inhibitors C. H2-receptors antagonists drugs D. M-cholin-receptor antagonists drugs 14. Which one of the following statements concerning the bacterium Helicobacter pylori is true? A. It is a Gram-positive rod It produces an enzyme called 'urease' that lowers the surrounding pH It exclusively colonises gastric-type epithelium On colonising the stomach it induces increased secretion of somatostatin from D cells Peptic ulcer disease 1. The etiological factor of peptic ulcer is: A. Candida B. (-hemolytic streptococcus C. Helicobacter pylori D. all answers are true 2. Invasive diagnostic test for Helicobacter pylori is: A. serology B. rapid urease test C. urea breath test D. all answers are true 3. Abdominal pain in the patients with the gastric or duodenal ulcer is characterized by, except: A. relationship to food B. localization to the epigastrium C. permanent D. episodic occurrence 4. Abdominal pain in the patients with the duodenal ulcer isn’t: A. nocturnal pain B. late pain C. hunger pain D. early pain 5. The generalized “board-like” rigidity of abdomen is observed in: A. gastric cancer B. gastric bleeding C. perforation D. gastric outlet obstruction 6. Upper GI radiography with a double-contrast barium study shows the only direct symptom of ulcer: A. Radiating folds B. Ulcer crater C. Nitch symptom D. Pyloristenosis 7. Complications of the peptic ulcer is, except: A. bleeding B. perforation C. gastric outlet obstruction D. ascitis 8. Free air beneath the diaphragm in erect chest radiograph is observed in: A. perforation B. gastric cancer C. gastric outlet obstruction D. gastric bleeding 9. The cornerstone of therapy for peptic ulcers is: A. prokinetic effect B. enhance mucosal defence C. inhibit acid secretion D. Helicobacter pylori eradication 10. Primary (first-line) H. pylori eradication therapy include, except: A. clarithromycin B. omeprazole C. bitsmuth D. amoxicillin 11. The most optimal Management of Upper gastrointestinal bleeding to provide Hemostasis is: A. Dicinon B. Rheopolyglucini C. Fresh frozen plasma D. Ac. Aminocapronici 12. The cardinal features of gastric outlet obstruction are, except: A. nausea B. vomiting C. abdominal distension D. ascitis 13. Primary (first-line) H. pylori eradication therapy include: A. omeprazole, amoxicillin or metronidazole, clarithromycin B. clarithromycin, misoprostol, bitsmuth C. aspirin, amoxicillin or tetracycline, clarithromycin D. omeprazole, tetracycline, ranitidine 14. Treatment of non-Hp ulcer include: A. PPI for 4 weeks B. PPI for 8 weeks C. PPI for 52 weeks D. Bismuth for 2 weeks 15. Quadruple therapies for H pylori infection include, except: A. Bismuth 525 mg qid, Metronidazole 500 mg qid, PPI bid, clarithromycin 500 mg qid B. Bismuth 525 mg qid, PPI bid, Metronidazole 500 mg qid, Tetracycline 500 mg qid C. Metronidazole 500 mg qid, PPI bid, clarithromycin 500 mg qid D. PPI bid, Bismuth 525 mg qid, Tetracycline 500 mg qid, 16. Maintenance therapy of peptic ulcer include, except: A. Long-term treatment B. On-demand treatment C. Prolong 52-weeks treatment D. Week-end therapy CHOLECYSTITIS 1. An overweight 41-year-old woman with a body mass index of 32 presents with a 5-day history of severe right upper quadrant pain. Initially the pain was intermittent, lasting for 2 hours then subsiding, but for the past 12 hours it has been constant. On examination she is pyrexial (38.5°C) and there is tenderness and rigidity in the right upper quadrant. Her white cell count is 18 × 109/l and C-reactive protein 130 mg/l. Liver function tests (LFTs) and amylase are within the normal range. Which of the following diagnoses is most likely? Biliary colic Acute pancreatitis Acute cholecystitis Choledocholithiasis 2. Which one of the following hormones causes contraction of the gallbladder and release of bile acids in the fed state? Insulin Cholecystokinin Glucagon Noradrenaline (norepinephrine) fed 3. Which of the following patterns of symptoms is most characteristic of acute blockage of the cystic duct by a gallstone? Recurrent epigastric pain, radiating to the back, lasting 2 hours then subsiding spontaneously Constant severe epigastric pain and recurrent vomiting Intermittent burning epigastric pain relieved by drinking milk Crushing, heavy epigastric pain radiating to the jaw associated with sweating, nausea and a terror of imminent death 4. Which of the following investigations is most appropriate for the initial diagnosis of acute symptomatic gallstone disease? CT of the abdomen Abdominal ultrasound scan Chest X-ray Plain abdominal X-ray 5. Risk factors for calculous cholecystitis are all except: Male sex Obesity or rapid weight loss Drugs (especially hormonal therapy in women) Pregnancy 6. Complications of acute cholecystitis are all except: Empyema of gallbladder Emphysematous cholecystitis Perforated gallbladder Primary sclerosing cholangitis 7. Which one of the following statements concerning biliary colic is incorrect: Sudden and complete obstruction of the cystic duct by stone Severe pain, the patient twists in agony until the pain resolves A bout of vomiting often precedes the beginning of the attack History of previous similar episodes 8. Which one of the following statements concerning cholecystitis is incorrect: Physical examination may reveal fever, tachycardia, and tenderness in the RUQ or epigastric region A palpable gallbladder or fullness of the RUQ is present in 30-40% of cases. Jaundice may be noted in approximately 15% of patients. The absence of physical findings rules out the diagnosis of cholecystitis. Intestine diseases 1. Functions of the small intestine are, except: A. absorption B. digestion C. protection against ingested toxins D. production of bile 2. Diarrhoea is: A. frequent porridge-like stool B. watery stool C. the passage of more than 200 g of stool daily D. pellety stool 3. The symptoms of malabsorption related to deficiency of iron are, except: A. anaemia B. angular stomatitis C. koilonychia D. proximal myopathy 4. The symptoms of malabsorption related to deficiency of vitamin B12 are, except: A. peripheral oedema B. peripheral neuropathy C. anaemia D. angular stomatitis 5. The symptom of night blindness related to deficiency of: A. iron B. vitamin D C. vitamin A D. albumin 6. The symptom osteomalacia in malabsorption related to deficiency of: A. zink B. calcium C. protein D. vitamin K 7. The symptoms of malabsorption related to deficiency of protein are, except: A. peripheral oedema B. poor wound healing C. muscle-wasting D. follicular hyperkeratosis 8. The sings of malabsorption are, except: A. hypoalbuminaemia B. increased prothrombin time C. hypocalciaemia D. increased hemoglobin 9. An immunologically mediated inflammatory disorder of the small bowel occurring in genetically susceptible individuals is: A. celiac disease B. Whipple’s disease C. Crohn’s disease D. ulcerative colitis 10. A multisystem disease with fat malabsorption, protein-losing enteropathy and gastrointestinal, nervous, pulmonary and musculoskeletal involvement is: A. ulcerative colitis B. celiac disease C. Whipple’s disease D. Crohn’s disease 11. Whipple’s disease is characterized by, except: A. constipation B. low-grade fever C. arthropathy D. steatorrhoea 12. A lifelong gluten-free diet - the only known effective treatment of : A. ulcerative colitis B. celiac disease C. Whipple’s disease D. Crohn’s disease 13. An idiopathic chronic recurring inflammatory process of the bowel that often leads to segmental transmural granulomatosis, fibrosis and obstructive symptoms, which can affect any part of the gastrointestinal tract is: A. ulcerative colitis B. celiac disease C. Whipple’s disease D. Crohn’s disease 14. The most common gastrointestinal tract involvement in Crohn’s disease is: A. esophagus B. pylorus and duodenum C. sigmoid and rectum D. terminal ileum 15. Which disease is characterized endoscopically by segmental lesions, separated by healthy areas - cobblestone: A. celiac disease B. ulcerative colitis C. Crohn’s disease D. Tropical sprue 16. Complications of Crohn's Disease don’t include: A. Hypersplenism B. Fistulae C. Acute toxic megacolon D. Intestinal obstruction Bowel diseases 1. Functions of the colon are, except: A. absorption water B. protein digestion C. absorption electrolytes D. propelling the faecal bolus 2. The bowel frequency of the normal population ranges: A. once day B. from 2 movements per day to 1 bowel action every second day C. from 3 movements per day to 1 bowel action every third day from 3 movements per day to 1 bowel action every week 3. In the assessment of diarrhoea, which one of the following clinical features most strongly suggests a colonic aetiology? Right iliac fossa pain Undigested food in stool Blood and mucus in stool Large-volume stool 4. Which one of the following physical consequences of malabsorption is incorrectly matched with the corresponding vitamin or mineral deficiency? Acrodermatitis enteropathica - Zinc Purpura and bruising - Vitamin K Peripheral neuropathy - Vitamin C Night blindness - Vitamin A 5. Which of the following would be least expected to provoke a relapse ('flare') of ulcerative colitis? Loss of job Cigarette smoking Viral laryngitis Course of antibiotics for falsely suspected urinary tract infection 6. A 19-year-old male presents with a 10-day history of bloody diarrhoea and lower abdominal pain associated with fever, malaise and anorexia. Which of the following investigations would be least helpful in establishing a diagnosis? Stool culture and microscopy Sigmoidoscopy and rectal biopsy Blood cultures and serological tests of infection Serum albumin 7. Which one of the following statements concerning intestinal complications of inflammatory bowel disease (IBD) is incorrect? In ulcerative colitis, colonic perforation may occur without the development of toxic megacolon The risk of developing colon cancer in ulcerative colitis is related to both the extent and the duration of colitis Both conditions may present with acute life-threatening haemorrhage Diarrhoea in ulcerative colitis may be due to enteroenteric fistulae 8. Which one of the following systemic complications of inflammatory bowel disease is not related to the activity of bowel disease? Conjunctivitis Primary sclerosing cholangitis Arthralgia Pyoderma gangrenosum 9. Which one of the following clinical features is least suggestive of irritable bowel syndrome (IBS)? Colicky abdominal pain relieved by defaecation Sensation of incomplete defaecation Symptoms disturbing sleep Alternating diarrhoea and constipation 10. Regarding the management of irritable bowel syndrome (IBS), which one of the following statements is true? Patients with constipation as the predominant symptom benefit most from tricyclic antidepressant therapy Elimination diets are the mainstay of treatment Reassurance alone may lead to resolution of symptoms All patients should be advised to increase dietary fibre 11. A functional bowel disorder in which abdominal pain is associated defaecation or a change in bowel habit with features of disordered defaecation and distension: A. ulcerative colitis B. Whipple’s disease C. celiac disease D. irritable bowel syndrome 12. Irritable bowel syndrome is characterized by, except: A. depression B. colicky abdominal pain C. bowel bleeding D. feeling of incomplete defaecation 13. Irritable bowel syndrome is wide overlap with, except: A. non-ulcer dyspepsia B. fever C. chronic fatigue syndrome D. dysmenorrhoea 14. The patient has severe ulcerative colitis with bloody diarrhoea and lower abdominal pain associated with fever, malaise and anorexia.. Which one of the following is true regarding the management? Nutritional support, if required, should be provided intravenously rather than enterally The patient should be treated with intravenous corticosteroids Surgery should not be considered until he has had at least 10 days of maximal medical therapy Sulfasalazine overcomes the need for surgery in around 80% of patients who fail to respond to corticosteroids Hepatitis 1. Which of the following is not a function of the liver? 1. Synthesis of clotting factors 2. Production of vitamin K 3. Production of glucose during fasting 4. Storage of copper 2. What a maintenance dose of prednisolone in chronic autoimmune hepatitis? 1. 100 mg 2. 0,1 mg 3. 1 mg 4. 10 mg 3. Which of the following viruses is not capable of causing infection without concurrent infection with another hepatitis virus? B) Hepatitis B C) Hepatitis C D) Hepatitis D E) Hepatitis E 4. Which is the morphological feature of alcoholic liver disease? 1. Gystiolymfoplazmocyt’s infiltration of portal fields 2. The presence of eosinophylic hyaline alcohol particles (Melory’s particles ) 3. Moderate fibrosis combined with degeneration of liver cells 4. Hyperplasia of stellate retikuloendoteliots 5. What are the normal sizes of liver (by Kurlov?) 1. . 14-14-15 A< 2. 7-6-6 A< 3. 14-9-12 A< 4. 10-9-8 A< 6. Which antibiotics are most hepatotoxic? 1. Natural penicillins 2. Semisynthetic penicillins 3. Cephalosporins 4. Tetracyclines 7. Raising of wich lab test isn t apply to cytolytic syndrome? 1. ALT 2. LDD 3. C-reactive protein 4. GGT 8. Which one of the following statements about hepatitis B infection is true? The route of infection does not affect clinical course It is caused by an RNA virus No vaccine is available It may cause cirrhosis 9. The drug of choice for treatment of chronic viral hepatitis in the phase of virus replication? 1. (-interferon 2. Voltaren 3. Vinpocetine 4. Cyclophosphan 10 Which drug is the drug of choice for treatment of autoimmune hepatitis? 1. Perlinganit 2. Prednisolone 3. Papaverine 4. Prazozin 11. What morphological change is not characteristic of chronic hepatitis B? 1. Gistiolimfoplazmotsit’s infiltration of portal fields 2. Hyperplasia of stellate retikuloendoteliots 3. Moderate fibrosis combined with degeneration of liver cells 4. Lesion of lobular structure of liver 12. A hospital inpatient is noted to have an elevated gamma-glutamyl transferase (GGT) with otherwise normal liver function tests. She is taking the following regular medications. Which one is most likely to have caused this abnormality? 1. Omeprazole 2. Paracetamol 3. Phenytoin 4. Ibuprofen 13. Of the following conditions, which is the most likely cause of jaundice accompanied by a seven-fold elevation of alanine aminotransferase and two-fold elevation of alkaline phosphatase? Viral hepatitis Acute cholecystitis Gilbert's syndrome Pancreatic carcinoma 14. Which one of the following is most suggestive of haemolysis as the cause of jaundice? Raised alanine aminotransferase (ALT) Presence of spider naevi Bilirubinuria Raised reticulocyte count 15. Which one of the following coagulation factors depends on vitamin K for complete synthesis in the liver? Factor V Factor VIII Factor IX Factor XI 16. A patient notices that the whites of her eyes have become yellow, her urine has been very dark for several days. Which of the following diagnoses is the most likely explanation for these symptoms? Cholestatic jaundice Hyperbilirubinaemia secondary to Gilbert's syndrome Rhabdomyolysis Dehydration 17. Which one of the following statements is true of hepatitis C infection? It is usually sexually transmitted Once infected, cure is impossible Liver transplantation is contraindicated due to the risk of reinfection of the transplanted liver Acute infection is usually asymptomatic 18. World-wide, which of the following is the most important risk factor for hepatocellular carcinoma? Alcoholic liver disease Haemochromatosis Non-alcoholic steatohepatitis (NASH) Chronic viral hepatitis 19. A 34-year-old woman is referred to the gastrointestinal clinic after her GP discovers abnormal liver function tests. She denies alcohol abuse or sexual risk factors. She received a blood transfusion in the UK in 2002 following a road traffic accident. Her past medical history includes obesity (body mass index = 42), type 2 diabetes mellitus and anxiety/depression. What is the most likely cause of her deranged LFTs? Occult drug overdose Alcoholic liver disease Non-alcoholic fatty liver disease Hepatitis B infection Cirrosis 1. What is the normal level of serum total protein? 1. 60-85 g /l 2. 20-45 g /l 3. 80-105 g /l 4. 100-125 g /l 2. Which of the following tests provides the most information about hepatic synthetic function within the last 12 hours? Activated partial thromboplastin time (APTT) Albumin Fibrinogen Prothrombin time (PT) 3. Which of the following is the first-line drug of choice to treat chronic ascites secondary to hepatic cirrhosis? Furosemide Spironolactone Digoxin Vasopressin 4. Which of the following statements about primary biliary cirrhosis is true? It is more common in men Pruritus is a more common presenting feature than jaundice A positive antinuclear antibody is diagnostic Immunosuppression prevents disease progression 5. Group designation B of Criteria for Child-Pugh classification includes Serum bilirubin (ľmol/L): A. 20-34 B. 30-45 C. 34.2-51 D. 40-55.5 6. Group designation B of Criteria for Child-Pugh classification includes Serum albumin (g/L): A. 20-30 B. 30-35 C. 35-40 D. 35-55 7. Hypersplenism result in: A. Spleen enlargement B. hypoproteinemia C. pancytopenia D. cholestasis 8. Complications of cirrhosis don’t include: A. secondary erytrocytosis B. variceal hemorrhage C. ascites D. hepatic coma 9. Bilateral asynchronous flapping of outstretched, dorsiflexed hands seen in patients with hepatic encephalopathy is: A. Xanthelasmata B. spider nevi C. fetor nepaticus D. Asterixis 10. The hallmark of Primary biliary cirrhosis : A. serum antimitochondrial antibodies B. cholesterol C. bilirubin D. alkaline phosphatase 11. Management of Primary biliary cirrhosis don’t include: A. Ursodeoxycholic acid B. Corticosteroids C. Cholestyramine D. Omeprasol 12. According to Grading of Hepatic encephalopathy: Subtle personality change; gross deficits in ability to perform mental tasks with intermittent disorientation for time or place is: A. Mild confusion B. Lethargy or apathy C. Somnolence to semistupor D. Coma 13. According to Grading of Hepatic encephalopathy: Marked confusion; gross disorientation, unable to perform mental tasks, disorientation to time and place, amnesia is: A. Mild confusion B. Lethargy or apathy C. Somnolence to semistupor D. Coma 14. Management of Hepatic encephalopathy includes: A. Lactulose B. Antibiotics C. Aminosteril-N-hepa D. all of above 15. Lactulose is: A. Enzymatic drug without bile acids B. Antibiotic C. diuretic D. osmotic laxative Pancreatitis 1. The most-common symptoms of chronic pancreatitis: 1. Abdominal pain 2. Steatorrhea 3. Nausea 4. All symptoms 2. The specific pancreatic enzymes: 1. Amylase 2. Elastase-1 3. Lipase 4. Phosphatase 3. The normal level of ph of pancreatic juice: 1. 1,0-1,2 2. 3,0-3,5 3. 7,5-9,0 4. 5,0-6,5 4. The daily volume of pancreatic juice: 1. 0,2-0,4 2. 0,8-1,2 3. 1,5-2,0 4. 0,6-0,8 5. The main symptoms of endocrine pancreatic insufficiency: 1. Hyperinsulinizm 2. Hypercorticoidism 3. Gipokortitsizm 4. Gipoinsulinizm 6. The main causes of chronic pancreatitis: 1. Alcoholism 2. Stenosis of the ampulla of Vater 3. Hereditary 4. All causes 7. The main tests to establish the diagnosis of chronic pancreatitis: 1. Ultrasound 2. CT 3. Abdominal X-ray 4. All tests 8. The main tests of pancreatic function: 1. Collection of pure pancreatic juice after secretin injection 2. Faecal pancreatic chymotrypsin or elastase 3. Oral glucose tolerance test 4. All tests 9. The complications of chronic pancreatitis: 1. Pseudocysts and pancreatic ascites 2. Extrahepatic obstructive jaundice 3. Duodenal stenosis 4. All complications 10. The complications of chronic pancreatitis: 1. Goblet cell intestinal metaplasia or Barretts esophagus 2. Portal or splenic vein thrombosis 3. Esophageal adenocarcinoma 4. All complications 11. The basic principles of the treatment of chronic pancreatitis: 1. Pain control 2. Bowel rest and hutritional support 3. Antibiotics 4. All 12. The diet for chronic pancreatitis: 1. A diet low in fat and high in protein and carbohydrates. 2. Include a daily diet of 2000-3000 calories, consisting of 1.5-2.0 g/kg of protein, 5-6 g/kg of carbohydrates, and 20-25% of total calories consumed as fat (about 50-75 g) per day. 3. Oral supplementation of fat soluble vitamins (A, D, E, and K) and vitamin B-12 is recommended. 4. All recommendations 13. Which of the following tests is most useful in the assessment of pancreatic exocrine function? Faecal elastase CT scan of abdomen Fasting blood glucose Lactose hydrogen breath test 14. A 55-year-old male presents with a 6-hour history of severe, constant upper abdominal pain radiating to the back. He drinks approximately 80 units of alcohol per week. On examination there is marked epigastric tenderness but no guarding or rebound tenderness. Which of the following tests is likely to be most useful in reaching a positive diagnosis? Plain abdominal X-ray C-reactive protein ECG Serum amylase Gastro-oesophageal reflux disease (GORD) 1. The most-common symptoms of gastroesophageal reflux disease: 1. Heartburnő k y V „ E z ş ť ł Ç Ę Ë V f Ä Ĺ NÍ΃„ž#€ĆÇ  2qé./TUz{56Ő‡ˆ­˛{-Ę ]hťÄçôxyŠ‹–—ŞBöîăîăîăîăîÚîăîÚîăîÚîăîÚîÎăîăîĹîĹîĹîöĹöĹîĹîĹîĹîöĹîĹîĹöĹîăîăîăîăîĹîĹîĹîăîăîhJ ÷\mH sH hJ ÷CJaJmH sH hJ ÷H*mH sH hJ ÷5\mH sH hJ ÷mH sH hJ ÷5mH sH ImŒĚő R ^ k y Ž ¸ ň V „ Ď  E z ˇ ů < ~ ł úřđđđđřččččřŕŕŕŕřŘŘŘŘřĐĐ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷$a$ł Ç  V f Ž Á N§Ę Whu„žĎŕó÷÷őííííőĺĺĺĺőÝÝÝÝőŃŃÉÉ & F gdJ ÷ & F ĆpgdJ ÷ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷[Ç 2qé/U{ž6ŐˆŽď5{-Ëţ úďďďďúääääúŮŮŮŮúÎÎÎÎúĂ $ & Fa$gdJ ÷ $ & F a$gdJ ÷ $ & F a$gdJ ÷ $ & F a$gdJ ÷ $ & F a$gdJ ÷$a$  ,]hqz†Ł˛ťÄĐçô˙ly‹—ôôôďääääďŮŮŮŮďÎÎÎÎďĂĂĂ $ & Fa$gdJ ÷ $ & Fa$gdJ ÷ $ & Fa$gdJ ÷ $ & Fa$gdJ ÷$a$ $ & Fa$gdJ ÷—¤ĽŞĚŢîBžBŠŹí'h˘Č D…ôďďęßßß×ŐÍÍÍÍŐĹĹĹĹŐ˝˝˝ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷ $ & Fa$gdJ ÷$a$$a$ $ & Fa$gdJ ÷B˝ž@AŹěí&'gh˘ĽłČ CD„…ŔÁĐĺ%&fg¨âć÷ LM‡ÁO`žÖc t Š Ž ž ą Đ č é í G!X!\!ş!Ç!Ő!Ö!č!ň!—"¤".#K#Č#óëóëÜóëÓëÓëÓëĘëÓëĘÓëÓëÓëÓëÓëÓëÓëĘÓëÓëÓëÓĘÓżÓĘÓżÓëÓĘÓóÓóÓżÓëżëłëŻëżëżëhJ ÷hJ ÷CJaJmH sH hJ ÷5\mH sH hJ ÷5mH sH hJ ÷\mH sH hJ ÷5B*\mH phsH hJ ÷mH sH hJ ÷B*mH phsH E…Áĺ&g¨ă M‡Áű.;O`”ŻžÖ÷ 1 ÷őííííőĺĺĺĺőÝÝÝÝőŐŐŐŐőÍ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷1 J c t ž ą Ŕ Đ é !(!7!G!X!˘!ş!Ç!Ö!ç!č!ň!X"t"Œ"÷÷÷őííííőĺĺĺĺőÝÝÝÝőŰÖĘĘ & F „äý`„äýgdJ ÷$a$ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷ & FgdJ ÷Œ"—"¤"Á"ň".#K#r#ť#Č#Ů#ď# $”$Ÿ$Ť$Ŕ$Đ$,%9%J%P%j%›%óóńĺĺĺĺńÝÝÝÝńŐŐŐŐńÍÍÍÍń & F(gdJ ÷ & F"gdJ ÷ & F!gdJ ÷ & F„äý`„äýgdJ ÷ & F „äý`„äýgdJ ÷Č#Ů#Ŕ$Đ$J%P%ń%&J&N&Ć&Ú&(8(‚(„(R)x)*!*ˇ*Ç*+5+|+Š+,*,”,Ÿ,ż,á,d-p-÷-.Š.”.Ď.Ř.B/O/Ł/Ź/î/ů/^0l0Ś0Ż0ě0ů0‘1Ÿ1T2c2É2Ň2â2ń23"3‡3˜3™3¤3X4n4´4É4ô4ő4'5A5ô5ţ5ż6Ě6B7`7b8Š899Ŕ9őíőíőíőíăíőíőíőíőíőíőíőíőíőíőíßíÖíÖíÖíÖíÖíÖíÖíÖíőíÖíÖíÖíőíßíÖíÖíÖíÖíÖíÖíÖíÖíÖíÖíÖíőíhJ ÷5mH sH hJ ÷hJ ÷CJmH sH hJ ÷mH sH hJ ÷5\mH sH T›%´%Í%ń%&†&¤&Ć&Ú&ň&((8(b(‚(„()0)R)~)–)ţ) *÷÷÷÷ęââââŕŘŘŘŘŇŕĘĘĘĘŕ & F%gdJ ÷ & F9gdJ ÷„h^„h & F:gdJ ÷ & F#gdJ ÷ $5$7$8$9DH$a$ & F$gdJ ÷ **!*3*]*‚*Ś*ˇ*Ç*ü* +++5+`+n+|+Š+–+ă+ń+˙+,÷÷÷őííííőĺĺĺĺőÝÝÝÝőŐŐĹ & F85$7$8$9DH$gdJ ÷ & F8gdJ ÷ & F&gdJ ÷ & F'gdJ ÷ & F)gdJ ÷ & F%gdJ ÷,*,x,†,”,Ÿ,ž,ż,á,=-X-d-p-}--ĺ-÷-.).C.s.~.Š.÷őíííÝ×ŐőőÍÍÍÍőĹĹĹĹő˝˝ & F*gdJ ÷ & F2gdJ ÷ & F3gdJ ÷„h^„h & F75$7$8$9DH$gdJ ÷ & F7gdJ ÷ & F8gdJ ÷Š.”..Ď.Ř.ă.ň.ý../7/B/O/[/Œ/—/Ł/Ź/ľ/ŕ/î/ů/00>0÷÷őííííőĺĺĺĺőÝÝÝÝőŐŐŐŐő & F.gdJ ÷ & F-gdJ ÷ & F,gdJ ÷ & F+gdJ ÷ & F*gdJ ÷>0M0^0l0z0ż0Đ0ě0ů0 1~1‚1†1‘1Ÿ1ń1@2T2c2s2‚2 2â2ó23÷÷÷÷őííííőĺĺĺĺőőőÝÝÝÝőŐŐ & F5gdJ ÷ & F4gdJ ÷ & F1gdJ ÷ & F0gdJ ÷ & F/gdJ ÷3"323]3i3w3‡3˜3™3Ł3¤3Ů3ó34X4n4Ł4´4É4Ý4ő4'5÷÷őííííçââőŇŇŇŇőžžž¸ő„h`„h & F= Ć8„„h^„`„hgdJ ÷ & F;„„h^„`„hgdJ ÷$a$„h^„h & F6gdJ ÷ & F5gdJ ÷'5A5q5…5Á5ô5ţ56#6;6o6†6˜6ż6Ě6 77*7B7`7Ö7ďďďďíÝÝÝÝíÍÍÍÍí˝˝˝˝í & F@„„^„`„gdJ ÷ & F?„„^„`„gdJ ÷ & F>„„^„`„gdJ ÷ & F<„„Đ^„`„ĐgdJ ÷Ö7ë7b8Š8°8@9†9Ŕ9ú9X:č:.;h;˘;<<Ü<=\=Ŕ=Î=ęęęęčŘŘŘŘčČČČČĂşşşĂľgd—Zž$ ĆĐa$$a$ & FC„„^„`„gdJ ÷ & FB„„^„`„gdJ ÷ & FA Ćp8„„^„`„gdJ ÷Ŕ9ú9ž:Ŕ:.;h;â<"=Ŕ=Î=Ň=>>>(>)>,>7>9><>F>G>J>U>W>Y>j>Œ>Ś>§>ł>ľ>Á>ä> ??öîăîöîöîÜÔĘÔÜÁÜśŠśÔĘԜœÔÔyÔśmśÔcÔh—ZžaJmH sH h—Zž5H*\mH sH h—ZžmH sH h—ZžB*mH phsH h—Zžh—ZžCJaJmH sH h—Zžh—ZžCJmH sH h—Zž5\aJmH sH h—Zž5\mH sH h—Zž5\aJh—ZžaJmH sH h—ZžmH sH  h—Zž5\hJ ÷5\mH sH hJ ÷mH sH hJ ÷5mH sH #Î=>)>9>G>W>v>‰>§>Á>Ô>?/?P?a?l?@@&@2@B@z@÷ňććá÷ćććć÷ćČćć÷ćććň¸$„h„˜ţ^„h`„˜ţa$gd—Zž Ć´„´„´-DMĆ ˙˙˙˙^„´`„´gd—Zžgd—Zž $„h^„ha$gd—Zžgd—Zž$a$gd—Zž?.?0?1?2?O?P?S?`?a?e?k?l?r?@ @@@@%@&@)@1@2@B@D@E@x@y@z@|@}@Ĺ@Ć@Č@É@AAAdAgAhAąA´AľAńAňAóAöAöîăÔöĘîĘÂăľăîöîöîă¨ăîöîĄî•Â•îăԊăî•Âî•Âî•Âî•Ę~îăh—ZžB*mH phsH h—Zž5\mH sH h—ZžB*mH phsH  h—Zž5\h—Zž5\aJmH sH h—Zž5\aJmH sH h—ZžmH sH h—ZžaJmH sH h—Zž5B*\mH phsH h—Zž5\mH sH h—ZžmH sH h—ZžaJmH sH 0z@Ć@AeA˛AóAB0BJBgBšBÔBńBC#CRCrCˆCĄCÁCD2D?DODóóóóëóóóóëóóóÓëóóÎÎëóóógd—Zž$ ĆĐ„Đ„˜ţ¤¤^„Đ`„˜ţa$gd—Zž$a$gd—Zž $„h^„ha$gd—ZžöAűAB B B/B0B2B3BdBfBgBiBjBƒBŒBŽBšBˇB¸BźBŇBÖB×BçBđBóBôBCC#C%C&C0CPCQCtCuCˆCĄCŚCŔCÁCçCDDD1D2D4D5D>D?DADBDđĺÝđÝĺÝŃÝČĺÝź˛ÝČݲŃݲÝŃݲÝđÝĺ§ÝźÝ˛źÝźÝŁœ‘œÝ‰Ýĺ‘ĺݑÝĺ݉h—ZžmH sH h—Zž5\mH sH  h—Zž5\h—Zžh—Zžh—ZžmH sH h—ZžaJmH sH h—ZžB*mH phsH h—ZžH*mH sH h—ZžB*mH phsH h—ZžmH sH h—Zž5\mH sH h—Zž5B*\mH phsH 6BDODQDRD`DcDdD‡DˆD‰DŒD™DšDœDDÂDĹDĆDßDâDăD˙DE.E3E>E?EBEMENEWEbEeEfEœEŸE­E°EŔEÂEĹEŇEÖEóEřEřęŰęřĎĹĎřş­şřĎŁřĎĹřĎŁřŁřŁřœ“œˆęřzĹřˆřĹşřrřĹřh—ZžmH sH h—Zž56\]mH sH h—Zžh—ZžmH sH h—Zž5\aJ h—Zž5\h—ZžaJmH sH h—Zž5\aJmH sH h—Zž5\mH sH h—ZžaJmH sH h—ZžB*mH phsH h—Zž5B*\mH phsH h—Zžh—Zž5\mH sH h—ZžmH sH ,OD`D‰DšDĂDŕDE0E?ENEWEbEŸE­EÂEÓEôEF1F@FKFöîââââîâÝĹĹľ°âââîâ°âgd—Zž$„h„˜ţ^„h`„˜ţa$gd—Zž$ ĆĐ„Đ„˜ţ¤¤^„Đ`„˜ţa$gd—Zžgd—Zž $„h^„ha$gd—Zž$a$gd—Zž„h^„hgd—ZžřEF1F@FCFJFKFXF[F\FmFnFoFšF›F´FľFšFÍFÎFëFěFýF G!G'G/G=G>GBGNGOGRG`GdGeGÄGĆGÇGHöîăîŮîŇîŮČŮîºҹîŮîČöîŮîö˜‹€îŮîtî˜e˜h—Zž5B*\mH phsH h—ZžB*mH phsH h—Zž5\mH sH h—Zž5\aJmH sH h—Zž5\mH sH h—ZžCJPJ h—ZžCJh—Zž5PJ\h—ZžPJaJ h—ZžaJh—ZžaJmH sH  h—Zž5\h—ZžaJmH sH h—Zžh—ZžmH sH h—ZžmH sH h—ZžaJmH sH 'KFXFoF›FľFÎFěF$G0G>GOGaGGÄGH-HbHšHŞHšHÍHúňççŰÖňŰ˝ŰŰ­ŰŰŰŰňŰŰŰ$„h„˜ţ^„h`„˜ţa$gd—Zž Ć´„´„´-DMĆ ˙˙˙˙^„´`„´gd—Zžgd—Zž $„h^„ha$gd—Zž $ & FNa$gdJ ÷$a$gd—Zžgd—ZžH H HeHgH˜H™HœHHŞHŹHŽH¸HšHťHźHÍHÝHŢHáHâH I III$I%I'I)I7I8IQIĄIłI´IĂIÄIÇIřěřŕÖŕřŕřËźŻËřŕřĄ‘ř†ř|řËźËřěřěÖřŕřqdřh—Zžh—ZžPJmH sH h—Zžh—ZžmH sH h—ZžaJmH sH h—Zž6]mH sH h—Zžh—Zž5PJ\mH sH h—Zžh—Zž5\mH sH h—Zž5\aJmH sH h—Zž5B*\mH phsH h—Zž5\mH sH h—ZžaJmH sH h—ZžB*mH phsH h—ZžB*mH phsH h—ZžmH sH %ÍHŢHI%I5IQIrIžI´IÄIŕIJ:JIJYJiJ}JÍJăJűJKKjKňâÖÖÖÖÎÖÉÖÄâÖÖÖÖÎÖÖÄÄÎgd—Zžgd—Zž$a$gd—Zž $„h^„ha$gd—Zž$„h„˜ţ^„h`„˜ţa$gd—Zž  ĆÄ„h^„hgd—ZžÇIßIŕIJJJJ"J8J9J=JHJKJLJ[J\J€JJŹJËJĚJÍJĐJâJăJĺJçJúJűJţJKKK KKK#KhKiKjKwKxK…K†K“K”K˜KĽKŤKđKôKőK LöîçŢîŇîŇĆîťîĆîĆîŇîöŇťîŇöî祟—çĽŢîöŇîöîöîöîöîöh—ZžmH sH h—ZžPJaJ h—ZžaJh—Zž5\aJh—Zž5\aJmH sH h—Zž5\mH sH h—ZžB*mH phsH h—ZžB*mH phsH h—Zž5PJ\ h—Zž5\h—ZžmH sH h—ZžaJmH sH 4jKxK†K”KŚKňK&LYLŽLĂLMBMzMąMéMęMëMűM0NLNqNôôĺŮŃŮŮŮŮŃŮŮŮĿٺѯŻ $ & FDa$gdJ ÷gd—Zžgd—Zž  ĆÄ„h^„hgd—Zž$a$gd—Zž $„h^„ha$gd—Zž$ & FK¤¤a$gdJ ÷ $ & FKa$gdJ ÷ L L!L"L%L(L)L=L>LTLULXLYL[L\LrLsL‰LŠLLŽLL‘L§L¨LžLżLÂLČL MMM&M'M=M>MAMDMEM[M\MvMwMyM|M}M“M”M­MŽM°MąMłM´MôęôęâÚęôęôęâĎġŠˇŠˇĎâęôęôęâęâęôęôęâęôęôęâęôęôę⒝h—Zžh—ZžmH sH h—ZžB*mH phsH h—Zž5H*\aJmH sH h—Zž5\aJmH sH h—Zž5\mH sH h—Zž5\mH sH h—ZžmH sH h—ZžmH sH h—ZžaJmH sH h—ZžH*aJmH sH 5´MĘMËMäMĺMçMčMéMëMűMýMN.N/N0NKNLNqN’N˘NĽNČNĺNůNüNOOOOOOO&O'O+O0O3OEO]O~OOóĺóĺóÚÍĹÁššŰ§°ĹžĹˇĹ”ҡ”ˇ”Ĺ|ˇqššgšh—ZžaJmH sH h—Zž5\mH sH h—Zž5\mH sH h—Zž5\aJmH sH h—ZžaJmH sH h—Zž5CJ\h—Zž5\aJ h—Zž5\h—ZžaJmH sH h—Zžh—ZžmH sH h—Zžh—ZžPJmH sH h—Zžh—ZžmH sH h—Zžh—ZžH*aJmH sH h—Zžh—ZžaJmH sH (qN’N˘NüNOO'O1O€OO˘O˝OĎOTDTETUTXTYTT’TľT¸TťTĹTĆTČTËT×TÝTćTéTëT U!U$U0UdNdPdVdfdhdóëáÖáëĚëĆëĚëáëşá믠“ëáë‹ë|ëáëncnh—Zžh—ZžmH sH h—Zžh—Zž5\mH sH h—Zž0J5\aJmH sH h—ZžmH sH h—Zž5\aJmH sH h—Zž5B*\mH phsH h—Zž5\mH sH h—ZžB*mH phsH  h—Zž0Jh—Zž0JmH sH h—ZžH*aJmH sH h—ZžaJmH sH h—ZžmH sH h—ZžB*mH phsH  hdjd†dˆddśd¸dždŔd&e(e.e0eLeReTerete†eˆeŠeČeff.f/f1f3fGfafcfdfefŠf‹fđâđŰŇÉÁľÁľÁľŞÁľ ” Œ Á }rŰÁh}Á}hÁ_Űh—Zž5\aJh—ZžaJmH sH h—Zž0J6]aJh—Zž0J6]aJmH sH h—Zž0JaJh—Zž0JaJmH sH h—ZžaJmH sH h—Zž5\mH sH h—ZžB*mH phsH h—ZžmH sH h—Zž5PJ\h—Zž5\aJ h—Zž5\h—Zžh—Zž5\mH sH h—Zžh—Zž5PJ\mH sH "ef‹fŁfäf$gogvg|g‹g§gńgőgůgŚh´hęhRišiîijôôčăŰĚĚččźąąčŹŰ§ččăgd—Zžgd—Zž $ & FHa$gdJ ÷$„h„˜ţ^„h`„˜ţa$gd—Zž$ & FI¤¤a$gdJ ÷$a$gd—Zžgd—Zž $„h^„ha$gd—Zž $ & FJa$gdJ ÷‹f”fŁf§făfäfčf#g$g'g=gLg\gog{g|g~gg‹ggŽg§gŞgşgĚg×gçgďgđgńgôgűgňëŕÎŕÁ­ÁĽ›ĽŒĽë‚ĽvĽŕkज़aĽŒ›WĽWĽh—ZžaJmH sH h—ZžaJmH sH h—Zž5\mH sH h—ZžB*mH phsH h—Zž56\]h—Zž0J6]aJmH sH h—ZžaJmH sH h—ZžmH sH &h—Zžh—Zž0J6CJ]aJmH sH h—Zžh—ZžCJmH sH "h—Zž0J56\]aJmH sH h—Zž5\mH sH  h—Zž5\h—Zž0J56\]aJűgüg~h€h˘h¤hŚh´h¸hşhćhčhęhđhiiiiPiRiXiriti|i~i˜i iěiîiôijjjj]j^jajƒj‹jőëőăőëÝăëÓëăĎÉÁÉÁÉĎăÓÁÓÁľăŚă™…™ăyÓănanh—Zž5\aJmH sH h—Zž5\mH sH h—ZžB*mH phsH &h—Zžh—Zž0J6CJ]aJmH sH h—Zžh—ZžCJmH sH h—Zž0J6]aJmH sH h—Zž0JaJmH sH h—Zž0JaJ h—ZžaJh—Zžh—ZžaJmH sH  h—ZžaJh—ZžmH sH h—ZžaJmH sH jh—ZžUaJ&j^jjšjĎjüj˝kČkŐkâkîkHlWldlollÂlČlŐlŢlúl%m/múîîîĺŐîîîîŐîîîîŐĘĘĘîÂî$a$gd—Zž $ & FFa$gdJ ÷$„h„˜ţ^„h`„˜ţa$gd—Zž„h^„hgd—Zž $„h^„ha$gd—Zžgd—Zž‹jŒjj’j“jŤjŹjĎjűjüjýjţj kkAk‡kŔkÇkĘkËkÓkŐk×kŘkâkĺkíkďkllóčŕÔŕČสŕžŕ”…”ŕ”ŕԔŕčviŕ”ŕžW"h—Zž0J56\]aJmH sH h—Zž5\aJmH sH h—Zž5B*\mH phsH h—Zž0J5\aJmH sH h—ZžaJmH sH h—ZžB*mH phsH h—Zžh—Zž5\mH sH h—Zžh—Zž5\aJmH sH h—Zž0JaJmH sH h—ZžB*mH phsH h—ZžmH sH h—Zž5\mH sH h—Zž5H*\mH sH ll"lFlGlJlKlYlZlklllqlrl€l‚lƒl lŔlÁlÂlÇlČlÔlŐlÝlŢlâlůlűlmm#m$m%m)m.m2mńçŘĚÄĚÄĚÄĚÄ̡ÄĚ­ŁĚÄ­Ä­˜‹˜Ä­ÄĚ|ŁĚÄj̘"h—Zž0J56\]aJmH sH h—Zž0J6]aJmH sH h—Zž5\aJmH sH h—Zž5\mH sH h—ZžaJmH sH h—ZžaJmH sH h—Zž5\aJmH sH h—ZžmH sH h—ZžB*mH phsH h—Zž0J6]aJmH sH h—ZžaJmH sH h—Zž0J6]aJmH sH $2mJmKmMm_m`mmmm‚m›mžmŸm°mđmôműmümţm˙mn n n nnn!n%n)n…n”n—n°nłn´nÄnŇn×nîăŰĎŰÁۡۨœ’ˆŰˇŰăylăŰ`ˇŰˇŰψۡۨœ’ˆŰh—ZžB*mH phsH h—Zž5\aJmH sH h—Zž5B*\mH phsH h—ZžaJmH sH h—ZžaJmH sH h—Zž0JaJmH sH h—Zž0J5\aJmH sH h—ZžaJmH sH h—Zžh—Zž5\mH sH h—ZžB*mH phsH h—ZžmH sH h—Zž5\mH sH "h—Zž0J56\]aJmH sH $/mKm`mmmńmüm nn"n×nçn÷nooBoRopo…o•oppóóęâóóóóŮÎÎÎÎÄóżżęâ´ $ & FGa$gdJ ÷gd—Zž dđ¤gd—Zž $ & FEa$gdJ ÷„Ä˙^„Ä˙gd—Zž$a$gd—Zž„h^„hgd—Zž $„h^„ha$gd—Zž×nćnoooo$o(o9o@oAoBoEoQoRoUonoroso„o…oˆoóěč×Ʊמ×Ć׌‚zobTEbT:h—Zžh—ZžmH sH h—Zž5B*\mH phsH h—Zžh—Zž5\mH sH h—Zž5\aJmH sH h—Zž5\mH sH h—ZžmH sH h—ZžaJmH sH "h—Zž0J56\]aJmH sH $h—Zž5OJQJ\^JaJmH sH )h—Zž5B*OJQJ\^JmH ph˙sH  h—Zž5OJQJ\^JmH sH  h—Zž5OJQJ\^JmH sH h—Zž h—Zž5\h—Zž5\aJmH sH ˆo”o•o§oŞoĂoĆoÇoŘopppp$p5pDpEpJpTp]p{pp€p–p—p¤pŚp§p˝pÚpçpóčŕÖŕÇťą§ŕ§Łš“ˆ“ŕąŕąŕ|ŕ|ŕˆm`ŕUh—Zž5\mH sH h—Zž5\aJmH sH h—Zž5B*\mH phsH h—ZžB*mH phsH h—Zž5\mH sH  h—Zž5\h—Zž5\aJh—Zžh—ZžaJmH sH h—ZžaJmH sH h—Zž0JaJmH sH h—Zž0J5\aJmH sH h—ZžaJmH sH h—ZžmH sH h—Zžh—ZžmH sH h—Zžh—ZžaJmH sH p%p5pEp}p”p¤p˝pŮpÚpýp4qPq_q‰qŹqÜqěqůqrr;rJrôôôěŕŕŕŕŰÓŰÎŕŕÉěŕŕŕŕěŕgd—Zžgd—Zž$a$gd—Zžgd—Zž $„h^„ha$gd—Zž$a$gd—Zž $ & FGa$gdJ ÷çpňpýp4q7qOqPqSq^q_qbqˆq‰qŤqŹqŻqŮqÜqßqěqíqîqďqřqůqüqrrrrr8rKrLrMr]r^rlr†r‡r™róčŢ×ÎĹčşč˛Ţ˛Ľ–˛Œ˛čó˛č}ތ˛Ţu˛Ţ˛Ţ˛č}˛Œ˛şh˛h—Zž5PJ\mH sH h—ZžmH sH h—Zž5B*\mH phsH h—ZžaJmH sH h—Zžh—ZžCJPJmH sH h—Zžh—ZžCJmH sH h—ZžmH sH h—Zž5\mH sH h—Zž5PJ\h—Zž5\aJ h—Zž5\h—ZžaJmH sH h—Zž5\mH sH h—Zž5\aJmH sH (Jr^rlr‡ržrŮrďrýrsĹsŇsäsósţst1tQtst˛tétűtu&ućÚÚŇÚćÚÚÍÄÄÄÄŇÚćÚÚŇÚćÚ„h`„hgd—Zžgd—Zž$a$gd—Zž $„h^„ha$gd—Zž Ć´„´„´-DMĆ ˙˙˙˙^„´`„´gd—Zž™rťrŰrÜrďrürýrŇsäs˙s t2t3t4tPtQtTtrtstvt¤tąt˛t´tćtětítútűtýtţtuuu%u&u+u@uousu„u…u†u‡uˆuŁu¤u§uŇuŐu v v0vöîâö×Ěî×îÂî׳ÂöîöŤ×ž‘×îÂî…Âî׳‘žîÂŤîÂîמ×î׳ŤöîŤîŤîÂh—Zž0JaJmH sH h—Zž5\aJmH sH h—Zž5\aJmH sH h—ZžmH sH h—Zž5B*\mH phsH h—ZžaJmH sH h—Zž5\mH sH h—Zž5\mH sH h—ZžB*mH phsH h—ZžmH sH h—ZžaJmH sH 4&u=uou…u¤uŇu v3vJvqvvšvšvĘv×v!w4wmwŽwŤwÇw×wxBxóëßĆßßëßĆßßëßĆĆßëßĆĆßëß Ć´„´„´-DMĆ ˙˙˙˙^„´`„´gd—Zž $„h^„ha$gd—Zž$a$gd—Zž $„h`„ha$gd—Zž0v6vIvJvLvMvqvtv€vvŸvśvşvťvÉvĘvËvĚvÍv×vÚv w!w"w$w4w7wHwgwjwnwowwŽwww‘wŤwŽwĆwÖw×wÚwëw xxxxAxBxCxDxExWxZxoxpx‚xřîřăÔÇřťłřŠřłŠłřžÔŠă‘ăřăŠřŠřŠřłŠłăžÔ‘řŠřŠřŠřŠřłŠłřžÔŠřŠřăh—Zž5\aJmH sH h—Zž5\mH sH h—ZžaJmH sH h—ZžmH sH h—Zž0JaJmH sH h—Zž5\aJmH sH h—Zž5B*\mH phsH h—Zž5\mH sH h—ZžaJmH sH h—ZžmH sH 9BxWxpx‚xƒxşxÄxéxüx yVyey‰yŸyąyťyńy˙y(z?zJzqzććÝŃÉŃććŃÉŃććÝÁÉźŃŃѡgd—Zžgd—Zž$a$gd—Zž$a$gd—Zž $„h^„ha$gd—Zž„h`„hgd—Zž Ć´„´„´-DMĆ ˙˙˙˙^„´`„´gd—Zž‚xƒx†x‡xŚxˇxťxźx˝xÄxĹxĆxÇxéxëxěxűxüxýx y y y#yWyXydyeyfygyhy‰yŒyžyŸyŁy°yąyťyńy(z–z zůz {¸{Ý{s|‡|öîöîöîćöćîŰĚöîÁöÁîÁöîöîćöćîćľöîöîÁ¨îš„ššyšh—Zžh—ZžmH sH hjWeh—ZžmHsHhjWeh—ZžmH sH hjWeh—Zž5\mH sH h—Zž5\aJmH sH h—ZžB*mH phsH h—Zž5\mH sH h—Zž5B*\mH phsH h—Zž5\mH sH h—ZžmH sH h—ZžmH sH h—ZžaJmH sH /qz{z‹z–z zÔzůz {7{R{’{¸{Ý{|"|Z|g|s|‡|œ|Ę|ç|}}1}}óóóóëóóóóëóćóóëóóóóëÚóóóë $„h`„ha$gd—Zžgd—Zž$a$gd—Zž $„h^„ha$gd—Zž‡|Ę|ç|Ś}Ĺ}~~€~™~ă~ń~>bĹÔęúA€[€lžő ‚E‚H‚I‚m‚‚‚ß‚ô‚żƒÁƒÂƒËƒ(„6„7„:„C„D„G„R„S„V„`„őçőŰőçőĐőĐőĐőÂőçőĐőŰőçőиőçőĐőçőçőŠ•őŠ•őŠ•Ű„ hjWeh—Zž5B*mH phsH 'hjWeh—Zž<OJPJQJ^JmH sH hjWeh—ZžB*mH phsH  jbđhjWeh—Zžh—Zžh—Zž5\mH sH h—Zžh—ZžmH sH hjWeh—Zž5mH sH hjWeh—Zž5\mH sH hjWeh—ZžmH sH ,}Ś}Ĺ}Ú}ę} ~~~,~<~h~t~€~™~Ľ~Ő~ă~ń~˙~ !>bm‡ľôôôôěŕŕŕŕěŕŕŰôěŕŰŕŕěŕŰŕŕěgd—Zž $„h^„ha$gd—Zž$a$gd—Zž $ & Fha$gdJ ÷ľĹÔęú5€A€[€}€Ś€&lžôőö ‚:‚E‚l‚ƒ‚›‚Ó‚ß‚óîóóćóîóóćóŰŰŰćÓÓćóóóóćó$a$gd—Zž $ & Fia$gdJ ÷$a$gd—Zžgd—Zž $„h^„ha$gd—Zž߂ô‚ƒ ƒƒƒ›ƒżƒĚƒăƒ%„7„D„S„a„Ľ„ˇ„Ë„Ú„ř„\…o……‘…¤…Ö…â…úîîćîîîîćÝÝÝÝćîîúîŘÝÝÝÝćîgd—Zž„h`„hgd—Zž$a$gd—Zž $„h^„ha$gd—Zžgd—Zž`„a„Ë„Ú„ú„ű„4…[…\…_…n…o…~………‚……‘…Ł…¤…††g†u†8‡[‡ś‡Ă‡Ä‡Đ‡;ˆ<ˆGˆHˆ[ˆ\ˆrˆsˆ‰ˆŠˆýˆ‰5Š8ŠęßÔßôߠߕ ß ‰}‰ęß ßoßÔßoßÔßÔß ß ß ‰ęß ßÔ߉hjWeh—Zž5\mH sH hjWeh—Zž5mH sH hjWeh—Zž5mH sH hjWeh—ZžmH sH 'hjWeh—Zž<OJPJQJ^JmH sH hjWeh—ZžB*mH phsH  hjWeh—ZžOJQJ^JmH sH h—Zžh—ZžmH sH hjWeh—ZžmH sH *hjWeh—Zž5<OJPJQJ^JmH sH +â…ń…††g†v†ˆ†Ś†ş†î†‡‡8‡[‡¤‡ś‡Ä‡Đ‡ß‡<ˆHˆ\ˆsˆŠˆĎˆóóóëćóóóëóóóóëóóáóÜÓÓÓÓë„h`„hgd—Zžgd—Zžgd—Zžgd—Zž$a$gd—Zž $„h^„ha$gd—Zžψوĺˆýˆ‰H‰„‰­‰ĺ‰ Š5ŠHŠ[ŠoŠ†ŠÇŠ‹q‹ł‹î‹'Œ?ŒWŒvŒóóóîćáŐóóĐÇóÇóĐÇÇÇÇĐÇÇÇ„h`„hgd—Zžgd—Zž $„h`„ha$gd—Zžgd—Zž$a$gd—Zžgd—Zž $„h^„ha$gd—Zž8ŠGŠHŠJŠKŠZŠ^ŠnŠoŠrŠyŠ…ŠŠŠ˘ŠŞŠľŠĘŠŢŠßŠ‹‹‹ ‹q‹s‹˜‹§‹ł‹ľ‹ě‹í‹î‹>ŒńáÖÉźÖźŽÖÉźÖɞÉ֍֍֍n֍֍֍cVÖhjWeh—ZžPJmH sH hjWeh—ZžmH sH $hjWeh—Zž5B*PJmH phsH hjWeh—Zž5mH sH !hjWeh—ZžB*PJmH phsH hjWeh—Zž6PJ]mH sH hjWeh—Zž<PJmH sH hjWeh—ZžPJmH sH hjWeh—ZžPJmH sH hjWeh—ZžmH sH hjWeh—Zž5<PJmH sH hjWeh—Zž5PJmH sH  >Œ?ŒWŒuŒvŒŒœŒâŽ÷Ž ČĚÍJŞ+’F’Ś’°’s“‰“Š“Ş“w”ś”–`–b–v–č–ý–ţ–@—p—q—˙—˜g˜|˜™™™f™n™y™š;šŞšÂš?›ëŕŇťŕŇŕŻŕŻ¤ŕ¤ŕŻŕŻŕŻŕ˜ŕŻŕŻŕŻŕŇŕ‘ˆŕ‘ˆŕ‘ŕ‘ŕ‘ŕŕ‘ŕ‘ŕ‘ŕhjWeh—ZžCJhjWeh—ZžPJ hjWeh—ZžhjWeh—Zž\mH sH hjWeh—ZžmHsHhjWeh—Zž5mH sH -hjWeh—Zž5<OJPJQJ\^JmH sH hjWeh—Zž5\mH sH hjWeh—ZžmH sH 'hjWeh—Zž<OJPJQJ^JmH sH 2vŒ‹ŒŒŒŒŽŒŒŒżŽÎŽâŽ÷Ž † ŞÍJŞâ"‘—‘ööîććîć××××ćČČČČćšššš$ & FV„h`„ha$gdJ ÷$ & FU„h`„ha$gdJ ÷$ & FT„h`„ha$gdJ ÷$a$gd—Zž$a$gd—Zž„h`„hgd—Zž—‘’+’F’S’j’Ś’°’Î’ü’“?“V“s“Š“Ş“ú“6”w”ś”Ű”+•÷čččč÷ÝÝÝÝ÷ŇŇŇŇ÷ĂĂĂĂ÷$ & Ff ĆĐa$gdJ ÷ $ & Fca$gdJ ÷ $ & Fba$gdJ ÷$ & FW„h`„ha$gdJ ÷$a$gd—Zž+•Ž•Ü•–`–a–b–u–v–§–ľ––č–ţ–—0—@—q—‚—Ď—Ú—đ—˙—˜g˜ôôôôěěääěŘŘŘÓěŘŘÓŘěŘŘŘÓěgd—Zž $„h^„ha$gd—Zž$a$gd—Zž$a$gd—Zž $ & Fga$gdJ ÷g˜|˜•˜ ˜ś˜ň˜ú˜™™™f™n™y™„™‘™ŕ™ő™ šš;šfšzš˜šŞšÂš?›Q›úîîîćîîúîáîúîîćîîîúćîîîúćúgd—Zž$a$gd—Zž $„h^„ha$gd—Zžgd—Zž?›P›Q›QœeœfœŹœťœźœîœ 7N`tu¸šežŽž˘žŁžśžĘžážBŸPŸ†ŸśŸĂŸďŸţŸ D H I U Y a e z ~ ” ůđĺůđĺůđĺÚĚÚĺÁˇŤĺڟÚ塍‘ĺÚĺ‘ĺڀĺ‘ĺqĺ‘ĚĺÚĺÚĺÚhjWeh—ZžB*mH phsH !hjWeh—ZžB*PJmH phsH hjWeh—Zž5\mH sH hjWeh—Zž9mH sH hjWeh—Zž5PJ\hjWeh—Zž5\h—Zžh—ZžmH sH hjWeh—Zž5\mH sH hjWeh—ZžmH sH hjWeh—ZžmH sH hjWeh—ZžPJ hjWeh—Zž,Q›f›y››)œ?œQœfœyœŹœźœĎœŢœîœ8N`uˆfž|žŽžŁžśžŸóóóëóóćóëćóóóáóÜćóáóóćóágd—Zžgd—Zžgd—Zž$a$gd—Zž $„h^„ha$gd—ZžŸŸ)Ÿ?ŸQŸÄŸÖŸěŸ˙Ÿ E V b { • – Ľ Ě ŕ ö Ą0ĄhĄtĄööööńööööńööööéäÜĐËĐĐÜĐgd—Zž $„h^„ha$gd—Zž$a$gd—Zžgd—Zž$a$gd—Zžgd—Zž„h`„hgd—Zž” • – Ľ ŕ ö łĄđĄńĄ×˘ń˘ŕŁ¤B¤G¤–¤Š¤źĽÂĽ\ŚjŚ¨K¨á¨ŠŕŠűŠ/ŤeŤ‚ŹžŹ­­‹­”­ćŽ&ŻőŻ°`°~°*ą3ą×ąçąq˛Á˛´V´p´r´Tľvľ ś śęśˇfˇiˇjˇvˇýˇ ¸šőçÜőŐőŐĚőŔőŔő´őŔő´őŔőŔőŔőŔőŔőŐőŐőŐőŔőŔőŔőŔőŔőŔőŐŹŐőŔőŔőŔőŔĄŔőŔő jahjWeh—Zž5hjWeh—Zž5hjWeh—Zž>*mH sH hjWeh—Zž5mH sH hjWeh—ZžPJ hjWeh—Zžh—Zžh—ZžmH sH hjWeh—Zž5\mH sH hjWeh—ZžmH sH ?tĄłĄńĄ'˘Ľ˘˝˘×˘ń˘Ł™ŁžŁŕŁ¤¤‰¤–¤Š¤ť¤˙¤ęĽóîÚŇÇÇÇÇŇźźźźŇąąąąŇ $ & F]a$gdJ ÷ $ & FZa$gdJ ÷ $ & FYa$gdJ ÷$a$gd—Zž & Ff Ć „h„^„h`„gdJ ÷gd—Zž $„h^„ha$gd—ZžęĽŚ)Ś\ŚjŚëŚL§Á§¨K¨Ń¨á¨Š Š"Š‹ŠťŠŕŠűŠ#Ş”ŞţŞ/ŤôôôôěááááěÖÖÖÖěËËËËěŔŔ $ & Fda$gdJ ÷ $ & Fea$gdJ ÷ $ & Faa$gdJ ÷ $ & F`a$gdJ ÷$a$gd—Zž $ & F^a$gdJ ÷/ŤeŤžŤEŹ[ŹpŹ‚ŹžŹŘŹçŹ­­9­t­‹­”­°­Á­Â­ŒŽćŽ&Ż…ŻóŻôŻôôěŕŕŕŰěŕŕŰŕěŕŰŕŕěěĐĐĐĐě $ & F_a$gdJ ÷gd—Zž $„h^„ha$gd—Zž$a$gd—Zž $ & Fda$gdJ ÷ôŻőŻ°<°`°~°Š°Á°Â°3ą4ąˇąÇą×ąçąöą÷ą9˛q˛Á˛ł/ł0łcł"´:´÷ëćććććććććŢŢŢŢćććććććććć & FlgdJ ÷gd—Zž $„h`„ha$gd—Zž$a$gd—Zž:´V´p´r´vľxľřľś ś ś'ś(śxśąśĐśęśˇˇ˘ˇŁˇ'¸(¸CšDš4şCşSşaşoşúúúúúúúúúúúúňňňňúúúúúúúúúúúú & FmgdJ ÷gd—ZžšCšSşaş0ťAť,źGźÎźŮźŻ˝Ĺ˝ż9żóż ŔĺÁÂ!Â*Â^ÂlÂWĂnĂđĂÄÄĻĆĆmĆ}ĆšĆÔĆÇ|Ç}ǁǎǏǞǟdzÇóčóčóčóčóčóčóčóčóčŕčóčóčóŐčóčÎčŔčÎčÎ豞ą~ąžąhjWeh—Zž<B*PJph!hjWeh—ZžB*PJmH phsH $hjWeh—Zž<B*PJmH phsH hjWeh—ZžB*mH phsH hjWeh—Zž5\mH sH  hjWeh—ZžhjWeh—ZžmHsHhjWeh—Zž\hjWeh—ZžmH sH hjWeh—Zž5mH sH -oşpş0ťAťVťjťť€ťÜťźź,źGźHźˇźÁźÎźŮźăźäźŻ˝Ĺ˝ú˝ žž÷÷ěěěěççßßßßçç××××ççĎĎĎĎ & FrgdJ ÷ & FpgdJ ÷ & FogdJ ÷gd—Zž $ & Fna$gdJ ÷$a$gd—Zžžžež‰žŹžż8ż9ż˘żťżÍżóż Ŕ ŔśÁĚÁĺÁ Â!Â*™ÂĂBĂúúňňňňúúęęęęúúââââúúÝúúŃ & Fq„h`„hgdJ ÷gd—Zž & FugdJ ÷ & FtgdJ ÷ & FsgdJ ÷gd—ZžBĂKĂWĂnĂäĂđĂÄ ÄÄeÄÄťÄéÄĹ}ņŏŚťĹĆ ĆĆĆ(ĆóóóîââââîÖÖÖÖîÍÍČÍîÍÍÍÍgd—Zž„h`„hgd—Zž & Fk„h`„hgdJ ÷ & Fj„h`„hgdJ ÷gd—Zž & Fq„h`„hgdJ ÷(ĆDĆZĆmĆ}ƌƹĆÔĆëĆöĆÇ}Ç~ǏǐǟǠdzÇŔÇÁÇÖÇđÇňÇČČ)Č*Č÷îîéî÷éîîîä÷îîîîîîîää÷îîîîgd—Zžgd—Zž„h`„hgd—Zž$a$gd—ZžłÇżÇŔÇÁÇŐÇÖÇďÇđÇňÇČČČ(Č)Č6Č7ČOČPČQČTČcČdȌȍȥȦȹȺȾČĚČÍČÎČŰČěČÉÉ+ÉaÉbÉnɘɌɧɊɞɿÉŔÉĂÉŰÉÜÉŕÉäÉĺÉćÉéÉí×íȾȾČí×íȵȵȵȪȵȪȵȵșľČ’Č™ľČ™Č™Č™ľČí×íșľČ™ľČŞ hjWeh—Zž!hjWeh—ZžB*PJmH phsH hjWeh—ZžmH sH $hjWeh—Zž<B*PJmH phsH hjWeh—ZžB*mH phsH *hjWeh—Zž5<B*PJ\mH phsH #hjWeh—Zž5B*\mH phsH 6*Č7Č8ČPČQČdȍȦȧȺȻČÍČÎČŰČɕɧɩɿÉŔÉÜÉÝÉĺÉćɐʑʣĘööööńéööööööäńńööööööööńéögd—Zž$a$gd—Zžgd—Zž„h`„hgd—ZžéÉęÉ÷ɏʐʑʔʢʣʺʻʼʿĘ×ĘŘĘŮĘÜĘŕĘáĘâĘäĘôĘËË"Ë#Ë2Ë3Ë7ËJËKËLËĺÖĹŹĄÖŎ֎Ö|hR|ÖŎ֡ÖŎ֎֎ÖŎÖ*hjWeh—Zž5<B*PJ\mH phsH 'hjWeh—Zž5B*PJ\mH phsH #hjWeh—Zž5B*\mH phsH $hjWeh—Zž<B*PJmH phsH hjWeh—ZžmH sH 0hjWeh—Zž<B*OJPJQJ^JmH phsH !hjWeh—ZžB*PJmH phsH hjWeh—ZžB*mH phsH 3hjWeh—Zž5B* OJPJQJ\^JmH ph3sH ŁĘĽĘťĘźĘŘĘŮĘáĘâĘËË#Ë$Ë3Ë4ËKËLË\ËnËo˕˖˗˥˦˲˳˴Ëöööööööńéööööööäńéöööööööögd—Zž$a$gd—Zžgd—Zž„h`„hgd—ZžLË\Ë^ËlËmËn˔˖ˤ˥˱˳˴ËÇËČËÉËĘËËËŘËŮË9ĚIĚJĚůîßΝߝߝߝߊ‘uůîgî\P\hjWeh—Zž5mH sH hjWeh—ZžmH sH hjWeh—Zž5\mH sH 6hjWeh—Zž5<B*OJPJQJ\^JmH phsH /hjWeh—Zž5B* OJQJ\^JmH ph3sH #hjWeh—Zž5B*\mH phsH $hjWeh—Zž<B*PJmH phsH !hjWeh—ZžB*PJmH phsH hjWeh—ZžB*mH phsH hjWeh—ZžmH sH  hjWeh—Zž´ËÉËĘËËËŘËŮËĚ Ě/Ě9ĚIĚ ĚűĚTÍŁÍÜÍÎÎ<ÎöńéáéŃĹĹĹĹĹŃŃŃĹ´§˘gd—Zž $dđ¤a$gd—Zž$„7dđ¤`„7a$gd—Zž ¤¤[$\$gd—Zž„Ĥ¤[$\$`„Ägd—Zž$a$gd—Zž$a$gd—Zžgd—Zž„h`„hgd—ZžJĚmĚnĚxĚỵ̆̇̐̑ĚÎĚĎĚŮĚÚĚäĚĺĚďĚđĚ#Í$Í/Í0Í;Í<ÍGÍH͏͐ͣ͢ͷ͸ÍÉÍĘÍÜÍ ÎâĘâĘł¤¤âʏ¤¤ł¤¤¤¤ł¤¤ł}¤¤l hjWeh—ZžOJQJ^JmH sH #hjWeh—Zž0J 5CJaJmH sH )hjWeh—Zž0J B*CJaJmH phsH hjWeh—ZžB*mH phsH ,hjWeh—Zž0J 5B*CJaJmH phsH .hjWeh—ZžB*fHmH phqĘ ˙˙˙˙sH :hjWeh—Zž0J B*CJaJfHmH phqĘ ˙˙˙˙sH # ÎÎÎ<ÎKÎYÎfΆΞΟέÎČÎÉÎĐÎŃÎÖÎăÎţÎĎDϏϜĎ,ĐAĐsĐŞĐŤĐŃĐÔĐíĐďäŮäÍť§•§äŮä‰}ocWäŮä}ä}äLä}äLhjWeh—ZžmH sH hjWeh—Zž\mH sH hjWeh—Zž\mH sH hjWeh—Zž5\mH sH hjWeh—Zž5mH sH hjWeh—Zž5mH sH #hjWeh—Zž5OJQJ^JmH sH &hjWeh—Zž5OJQJ\^JmH sH #hjWeh—Zž5OJQJ^JmH sH hjWeh—Zž5mH sH hjWeh—ZžmH sH hjWeh—ZžmH sH  hjWeh—ZžOJQJ^JmH sH <ÎKÎYΟήεÎÉÎÖÎĎAĎpϏϜĎĘĎđĎĐ,ĐAĐpĐŤĐŃĐîĐŃFŃúúéúúúúŕúúúú×úúúú×úúúú΄Ä`„Ägd—Zž„h`„hgd—Zž„7`„7gd—Zž$„7dđ¤`„7a$gd—Zžgd—ZžíĐŃEŃFŃUŃVŃ{Ń|ыђћўѫѹŃÓ(ӍӞÓ{ՊŐőÚΞ°ž°žĄ•‰oUőI>2>2hjWeh—Zž5mH sH hjWeh—ZžmH sH hjWeh—Zž5mH sH 2hjWeh—Zž0J"B*fH@mH phqĘ ˙ćěůsH 2hjWeh—Zž0J"B*fHmH phqĘ ˙ëďůsH hjWeh—Zž\mH sH hjWeh—Zž\mH sH hjWeh—Zž0J!CJmH sH hjWeh—Zž5CJmH sH hjWeh—Zž0J!5CJmH sH hjWeh—Zž5mH sH 5hjWeh—Zž0J"5B*fH@mH phqĘ ˙ćěůsH hjWeh—ZžmH sH FŃVŃ|ыђѹŃöŃŽŇÓ(ӍӞӲÓÉÓćÓKŐbŐvŐ{ՊՋŐúúúúçŘËËËø¸¸¸Ă­­­­Ă $ & F\a$gdJ ÷ $ & FXa$gdJ ÷$a$gd—Zž -DMĆ ˙˙˙˙gd—Zž-D@&MĆ ˙˙˙˙gd—Zž„h-D@&MĆ ˙˙˙˙`„hgd—Zžgd—ZžŠŐ‹Ő´ŐÔŐňŐÖ¸+¸,¸o¸p¸y¸z¸{¸¸Ą¸­¸˛¸и š(š4š5šRšpšrš—š§š­šŽšŰšůšAşQştş’şőîă×ăŐăĆăĆšĆă­ăœă×ă‰v‰ă×㭜eZă×ă­ă×hjWeh—ZžmH sH !hjWeh—Zž0J"B*mH phsH $hjWeh—Zž0J"5B*mH phsH $hjWeh—Zž0J"5B*mH phsH !hjWeh—Zž0J"B*mH phsH hjWeh—Zž5mH sH hjWeh—Zž0J#mH sH jhjWeh—ZžUmH sH UhjWeh—Zž\mH sH hjWeh—ZžmH sH hjWeh—ZžhjWeh—ZžmH sH #‹Ő´ŐôŐ¸¸}¸¸Ҹ븚 š5šrš—šŁšŽšžšűšş3şAşQş”şŚşąşĎşúęĺĺĺĺęĺĺĺĺÜĺĺĺĺÜĺĺĺĺęĺĺĺ„Ä`„Ägd—Zžgd—Zž„Ĥ¤[$\$`„Ägd—Zžgd—Zž 2. Regurgitation 3. Trouble swallowing ( HYPERLINK "http://en.wikipedia.org/wiki/Dysphagia" \o "Dysphagia" dysphagia) 4. All symptoms 2. The most-common complications of gastroesophageal reflux disease: 1. Esophageal strictures 2. Barrett's esophagus 3. Esophageal adenocarcinoma 4. All complications 3. The atypical symptoms of gastroesophageal reflux disease: 1. Chronic cough, laryngitis, asthma 2. Jaundice 3. Ascites 4. All symptoms 4. The atypical symptoms of gastroesophageal reflux disease: 1. Erosion of dental enamel 2. Dentine hypersensitivity 3. Sinusitis 4. All symptoms 5. Factors that can contribute to gastroesophageal reflux disease: 1. Hiatal hernia 2. Obesity 3. Zollinger-Ellison syndrome 4. All factors 6. Factors that can contribute to gastroesophageal reflux disease: 1. Cachexia 2. Hypercalcemia 3. Portal hypertension 4. All factors 7. Medications of gastroesophageal reflux disease: 1. Proton pump inhibitors 2. Gastric H2 receptor blockers 3. Antacids 4. All 8. Medications of gastroesophageal reflux disease: 1. Glucocorticosteroids 2. Prokinetics 3. Hepatoprotectors 4. All 9. The standard surgical treatment of gastroesophageal reflux disease: 1. The Nissen fundoplication 2. Highly selective vagotomy 3. Transoral incisionless fundoplication 4. All 10. The surgical treatment of gastroesophageal reflux disease: 1. The Nissen fundoplication 2. Highly selective vagotomy 3. Transoral incisionless fundoplication 4. All 11. Another names of gastroesophageal reflux disease: 1. Gastro-oesophageal reflux disease (GORD) 2. Gastric reflux disease 3. Acid reflux disease 4. All names 12. The main investigations of gastroesophageal reflux disease: 1. Ambulatory esophageal pH monitoring 2. Barium swallow X-rays 3. Esophagogastroduodenoscopy 4. All investigations 13. Biopsies of gastroesophageal reflux disease may show: 1. Lymphocytic inflammation 2. Neutrophilic inflammation 3. Eosinophilic inflammation 4. All kinds of inflammation 14. Biopsies of gastroesophageal reflux disease may show: 1. Edema and basal hyperplasia 2. Goblet cell intestinal metaplasia or Barretts esophagus 3. Dysplasia or pre-cancer 4. All 15. GERD is caused by: 1. Failure of the cardia of the stomach 2. Incompetence of the higher esophageal sphincter 3. Changes in the barrier between the duodenum and the stomach 4. All 16. Which one of the following factors does not predispose to gastro-oesophageal reflux disease (GORD)? Pregnancy High intake of coffee Weight loss Hiatus hernia ’şĎşŢşťť$ť%ť,ť.ť?ťCťUťfťxťyť—ť˜ť™ťŔťÁťâťéťűťüťźźźź3ź5źDźHźWź‚ź…źőéőÝőÎżőéőĽő˜őÝő˜őŒőé˜őÝő˜őrőéőXő˜2hjWeh—Zž0J"B*fH@mH phqĘ ˙ćěůsH 2hjWeh—Zž0J"B*fHmH phqĘ ˙˙˙˙sH hjWeh—ZžH*mH sH hjWeh—Zž0J!mH sH 2hjWeh—Zž0J"B*fHmH phqĘ ˙˙˙˙sH hjWeh—ZžB*mH phsH hjWeh—ZžB*mH phsH hjWeh—Zž\mH sH hjWeh—Zž5mH sH hjWeh—ZžmH sH "Ϻ޺!ť.ť?ťWťfť™ť´ťŐťâťéťź5źDźXź_źŚźĂźáź ˝˝R˝o˝˝úęúúúúáúúúúáúúúúáúŐŐŐŐúŐ ¤¤[$\$gd—Zž„Ä`„Ägd—Zž„Ĥ¤[$\$`„Ägd—Zžgd—Zž…ź†ź¤źŚź­źĂź.˝1˝2˝P˝Y˝o˝ˇ˝ž˝Ď˝Ó˝Ô˝žžQž_žlžžžţžż%żDżŠżČżŮżřżzŔ‚Ŕ…Ŕ†Ŕ™ŔŔŔŘŔŢŔöŔ÷ŔÁ"Á2Á3Á:Á;ÁőéőÝĎőÂőéőśőÝĽÂőéőé—éőéőÝőéőÝőéőÝőÝőÝőˆőÝőĽőÝő}hjWeh—ZžmH sH hjWeh—ZžB*mH phsH hjWeh—Zž5\mH sH !hjWeh—Zž0J"B*mH phsH hjWeh—Zž]mH sH hjWeh—Zž0J!mH sH hjWeh—Zž5]mH sH hjWeh—Zž5mH sH hjWeh—Zž\mH sH hjWeh—ZžmH sH /˝ˇ˝ž˝ô˝ ž:žQž^žŸžĆžßžţžżNżlżŠżŠżČżŔ"Ŕ^ŔzŔŔ™ŔÁŔóóăóóóóóóóóóăŢŢŢŢŐŢŢŢŢŢŢ„Ä`„Ägd—Zžgd—Zž„Ĥ¤[$\$`„Ägd—Zž ¤¤[$\$gd—ZžÁŔôŔ3Á:Á¤ÁŻÁĆÁÓÁáÁâÁăÁúúúňççççňĺ $ & F[a$gdJ ÷$a$gd—Zžgd—Zž ;Á<ÁĆÁÓÁâÁăÁříáíŮhJ ÷mH sH hjWeh—Zž5mH sH hjWeh—ZžmH sH h—ZžmH sH ,1h°‚. °ĆA!°Đ"°ę#ƒ$n%°°Ä°Ä Ä^$ ˜˜žžžžžž666666666vvvvvvvvv666666>666666666666666666666666666¨666666666¸666666666666666666666666666666666666666666666666666666666666666666666666666°62ŔĐŕđ 0@P`p€ŔĐŕđ2(Řč 0@P`p€ŔĐŕđ 0@P`p€ŔĐŕđ 0@P`p€ŔĐŕđ 0@P`p€ŔĐŕđ 0@P`p€ŔĐŕđ 0@P`p€8XřV~_HmHnHsHtHB`ń˙B 1KG=K9CJ_HaJmHsHtHL@L  03>;>2>: 1$$@&a$5\mH sH T@T  03>;>2>: 2$$„h@&^„ha$5\mH sH ^@^ —Zž 03>;>2>: 3$¤đ¤<@&5CJOJPJQJ\^JaJ^@^ —Zž 03>;>2>: 4$¤đ¤<@&5CJOJPJQJ\^JaJb@b —Zž 03>;>2>: 5 ¤đ¤<@&$56CJOJPJQJ\]^JaJ\@\ —Zž 03>;>2>: 6 ¤đ¤<@&5CJOJPJQJ\^JaJN@N —Zž 03>;>2>: 7 ¤đ¤<@&OJPJQJ^JT@T —Zž 03>;>2>: 8 ¤đ¤<@&6OJPJQJ]^JBA`ň˙ĄB A=>2=>9 H@8DB 0170F0\i@ó˙ł\ 01KG=0O B01;8F0 :V ö4Ö4Ö laö .k`ô˙Á. 0 5B A?8A:0 Vţ/˘ńV —Zž03>;>2>: 3 =0:5CJOJPJQJ\^JaJVţ/˘V —Zž03>;>2>: 4 =0:5CJOJPJQJ\^JaJ\ţo˘\ —Zž03>;>2>: 5 =0:$56CJOJPJQJ\]^JaJ8ţo˘!8 —Zž mmdefinition16]*ţo˘1* —Zžsymbol1;€>ţo˘A> —Zž mmhheadtitle1 56\],ţo˘Q, —Zž mmdrugtermHţobH —Zžmmpara dP¤ B*OJQJ^Jph0X`˘q0 —Zž K45;5=856],W`˘, —Zž!B@>3895\Pţo’P —Zžmmfhead d,¤-5B*OJQJ\^JphVţ/˘ĄV —Zž03>;>2>: 6 =0:5CJOJPJQJ\^JaJPţ/˘ąP —Zž03>;>2>: 7 =0:CJOJPJQJ^JaJVţ/˘ÁV —Zž03>;>2>: 8 =0:6CJOJPJQJ]^JaJpC`Ňp —ZžA=>2=>9 B5:AB A >BABC?><$„h„˜ţ^„h`„˜ţa$ CJmH sH dţ/˘ád —ZžA=>2=>9 B5:AB A >BABC?>< =0:CJaJmH sH D^`ňD —Zž 1KG=K9 (251)¤d¤d[$\$4ţo˘4 —Zž long_text1CJaJ.ţo˘. —Zž mw-headline6ţo˘!6 —Zž short_text1CJaJ8U`˘18 —Zž 8?5@AAK;:0 >*ph˙PK!‚Šźú[Content_Types].xmlŹ‘ËjĂ0E÷…ţƒĐśŘrş(ĽŘ΢Iw},Ňäą-j„4 Éßwě¸Pş-t#bΙ{UŽă “óTéU^h…d}㨍ôűî)ť×*1Pƒ'Źô “^××Wĺî0)™ŚTéž9<“l#¤Ü$yi}ĺ;Ŕ~@‡ćś(îŒőÄHœńÄĐuů* D× zƒČ/0ŠÇ° đűů $€˜ XŤÇ3aZ˘ŇÂŕ,°D0j~č3ßśÎbăí~i>ƒŘÍ3ż\`ő?ę/ç[ŘŹśGéâ\Ä!ý-ŰRk.“sţÔť..—ˇ´aćż­?˙˙PK!ĽÖ§çŔ6 _rels/.rels„ĎjĂ0 ‡ď…˝ƒŃ}QŇĂ%v/ĽC/Ł}á(h"ŰëŰOÇ ť„¤ď÷Š=ţŽ‹ůá”ç šŞĂâC?Ëháv=ż‚É…¤§%[xp†Ł{Űľ_źPŃŁ<Í1ĽHś0•ˆŮOźRŽBdŃÉŇJEŰ4b$§‘q_טžŕ6LÓőR×7`Ž¨É˙łĂ0̞OÁŻ,ĺEn7”LiäbĄ¨/ăS˝¨eŞÔĐľ¸ůÖý˙˙PK!ky–ƒŠtheme/theme/themeManager.xml ĚM Ă @á}ĄwŮ7cť(Eb˛ËŽťöCœAǠҟŰ×ĺăƒ7Îß՛K Y,œ ŠeÍ.ˆˇđ|,§¨ÚHĹ,láÇćéxÉ´ßIČsQ}#Ր…­ľÝ Öľ+Ő!ď,Ý^š$j=‹GWčÓ÷)âEë+& 8ý˙˙PK! źĆľƒtheme/theme/theme1.xmlěYĎnEż#ńŁ˝ˇą;Ł8UěŘ ´iŁŘ-ęqźďN3ťłš'ő­JH DA¨\8 R‹¸´ďŕ>C ŠÔWŕ›™]{'ސ¤ ‚ć{gß˙?óÍxĺň݈Ą]"$ĺqÝ+_,yˆÄ>ďÓ8¨{7ťí K’ Ç}ĚxLęވHďňęťďŹŕe’ˆ  ĺ2Ž{ĄRÉňܜôaˋ??<ťߟÂçdžśżSÖr$›L ]Ěęˆîó˝.šŤ<Ä°Tđ˘î•ĚŸ7ˇş2‡—S"ŚŽĄÍŃľÍ_J—ôwćLô&BËíJíŇú„ż05‹kľZÍVyÂĎ°ďƒĺV—<ĎJ{ŠÜČxć@öë,ďfŠZ޸ř˙…kFŁZKuąL Č~­Ěŕ—J‹•ľyo@_ÁWkÍ梃7 ‹_œÁˇ/Ő+.ހBF㝴hťrŸ@œm—žTJáSdĂ$Ű´ˆŐis/Âw¸h&dXŃŠQB؇Doâ¨'(Öń2Áš7vɗ3KZ6’ž ‰Ş{ď'ŠfĘďĺ“ď_>y„÷î˙|x˙ţáţ–‘Cľă OőâŰOţ|xýńčŤ>+ĆË<ţ×>üĺé§Ĺ@(§Š:Ď??říńÁó/>úýťđ5{yx—FD˘ëdmó 3^q5'=q6Šnˆižb-$Žą–RŔżĽB}}„YGq=xK@;)^Ţqî„b¨häŤaä79g . ˝pUËĘšš;Œƒbáb˜Çmcź[$ť‰c'ž­a}5KKÇđfH5ˇŽHLŇďř!ÖÝŚÔńë&ő—| ĐmŠ˜ş¤K{N6M‰6hqŮ ńv|ły 58+˛zěşH¨ Ě ”ďć¸ń *ąěâˆĺ~ Ť°HÉÎHřy\K*ˆt@G­>‘˛ˆć†{sAżŠĄƒ†}“")Ý)ây sžGŽófˆŁ¤ŰĄq˜Çž'w E1Ú⪞ÉÝ ŃĎî[”8á>šܤŁŇ4Aô›ĄĐą„ÖítŕˆĆ׎…~lsŕüÚ14Ŕç_>,ČŹ7ľŻÁžTT GÚďq¸ŁMˇÉEŸžů=wă-i>ťńźmšo[Ž÷ŸošÇŐóií´ˇBŰŐsƒ’ÍȝzbPĆ:jÄČ5i†f űFż ‹š9P’ɉ* ákÚç\ °ĄA‚Ť¨ ;!N`ŕ.{šI SցD —pđ3˅ź5†veU} °ýAbľÉűvyA/gç† łű氚 ZĐ N+láRĘĚ~ae­ÔŠĽ•jŚő9Ň&&CLgMƒĹ‰7a A0ƀ—áHŻEĂA3Ň×~ˇ{q…ó ‘ qŸ¤1ŇvĎƨl‚”劚9€Ü)ˆ‘>žŕľœ´šfűŇN¤ź¸Ę1â˛č˝N”˛ žFI×ń‘rdqž8YŒöę^­:_ő“ş7€3.|ˆşÔ3 fÜ%ůJŘ´?ą˜M•OŁYË s‹  ×Öď3;} R­cÚÔ0ŻŇ`ą–dőŸŻ‚[ϲ鯠ĹÂ$ĂżŚřŃ - ˆŻňÁέhßŮÇ´•ňĄ"˘ö÷P Ĺ6†đëT{úTÂU…éúîŮ´ˇÍ+ˇ9§E—żÝ28ťŽYâ´ÝęÍ*ŮÂMOt0O9őŔśBݍqg7Ŕü9™’Oă˙™)z?›ƒ…žŽ€7ż#]Żu rčBIHýś€AÂôȸŤ…אTp˙l>Ů՟ść,SÖpTŰ4@‚Â~¤BAČ´%“}'0+§{—eÉRF&ŁręĘÄŞÝ#ť„uu\Ô{ť‡BHuÓMŇ6`pGóĎ}N+¨č!'_oN™ě˝śţéÉÇ3ĺöa3ĐdţŸ¨X°ŤZzCží˝yCô‹é˜UÉŞ„ĺś‚ZZöŻ¨ÂˇZŰąf,žŻfĘAg-†ĹÉ@”ŔýŇ˙`˙ŁÂgö— ˝Ąvů6ôV?Dhf6Őěŕtƒ´‹=œě˘M&ÍĘş6´×˛Íúœ'݉Ü#Î֚&Ţgtöd8sĹ9ľxžÎN=ěřÚŽëjˆěŃ…ĽAv°11ż‚ĺĽâ˝;ču¸ď2%M2ÁoNĂčŮ1uĹo%ŇŐż˙˙PK! ѐŸś'theme/theme/_rels/themeManager.xml.rels„M Â0„÷‚wooÓş‘&݈ЭÔ„ä5 6?$Qěí Ž,.‡až™iť—Éc2Ţ1hŞ:é•qšÁm¸ěŽ@RN‰Ů;d°`‚Žo7íg‘K(M&$R(.1˜r'J“œĐŠTů€Ž8ŁVä"ŁŚAČťĐH÷u} ń›|Ĺ$˝b{Ő–Pš˙łý8‰g/]ţQAsم(˘ĆĚŕ#›ŞLĘ[şşÄß˙˙PK-!‚Šźú[Content_Types].xmlPK-!ĽÖ§çŔ6 +_rels/.relsPK-!ky–ƒŠtheme/theme/themeManager.xmlPK-! źĆľƒŃtheme/theme/theme1.xmlPK-! ѐŸś'ş theme/theme/_rels/themeManager.xml.relsPK]ľ /ÍÎ˙˙˙˙BČ#Ŕ9?öABDřEHÇI L´MOÎP´R,TQUHW"Y \o]–^˝_Çahd‹fűg‹jl2m×nˆoçp™r0v‚x‡|`„8Š>Œ?›” šłÇéÉLËJĚ ÎíЊՒş…ź;ÁăÁkqu~€‚ƒ…‡‰‹ŒŽ‘“”–—™šœŸ ˘ŁĽŚ§ŠŞŹŽ°˛´¸ťźÁÄĘĎŃÓŐÖŘÚáăćł  —…1 Œ"›% *,Š.>03'5Ö7Î=z@ODKFÍHjKqNKQT%WNY(^Xaefj/mpJr&uBxqz}ľ߂â…ĎˆvŒ—‘+•g˜Q›ŸtĄęĽ/ŤôŻ:´oşžBĂ(Ć*ČŁĘ´Ë<ÎFыŐĎş˝ÁŔăÁlmnoprstvwxyz{|}„†ˆŠ’•˜›žĄ¤¨Ť­Żąłľśˇšş˝žżŔÂĂĹĆÇČÉËĚÍÎĐŇÔ×ŮŰâäĺOC“CžCäW(X:XwĂťĂĹĂ/ÍX4˙ŒX4˙ŒX˙Œđ8đ@ń˙˙˙€€€÷đ’đđ0đ( đ đđB đS đżË˙ ?đ˙˙ TreatmentDietż1Íż1Í˙˙ ,á$ Üá$ Œâ$ <ă$ ěă$ œä$ „ĺ$ 4ć$ ő! źő! Üô! Üö! l÷!! ř!" Ěř!#  ů!$ Lů!% üů!& Źú!' `8( ”`8) Da8* ôa8˘|E†xŠ×‹‘蓇šW˘d˘q˘˘Ś0ŞY­+Ž+Ž°ŻžŻĚŻÜŻżęż2Á1Í     ¨|J†}ŠÜ‹‘ě“Œš\˘h˘v˘ƒ˘•Ś5Ş^­-Ž-Ž´ŻÂŻŃŻáŻ żîż7Á1Í C*€urn:schemas-microsoft-com:office:smarttags€metricconverter€9 *€urn:schemas-microsoft-com:office:smarttags€place€B*€urn:schemas-microsoft-com:office:smarttags€country-region€ °ŕ$€1. A€10. A€105 g€11. A12 A<€12. A€125 g€14. A15 A<€16. A€19. A€200 g€3. In€38.5°C€45 g6 A<€6. A€75 g8 A<€85 g €ProductID     ;J—Ł&@KWaˇ ż Á Ë Ň Ý     * Ç Ó O [ ô ˝Éţ  +]ghpqyz…Łą˛şťĂÄĎçňôţ˙yŠiv'-.:őůt€ŠŒ•—Ł§ąÓÔáíďţ FWŽ’”ŸŠP_CQfl|€ťŔŐŢü  ĎÜ  K!U!Š!”!˙!"”""Ÿ"ź"Ň"ŕ"ĺ"ó"'#5#Ň#ŕ#$($[$i$s${$~$‰$Š$“$”$œ$ś$Ä$Ď$×$Ř$â$ă$ď$ň$ü$%#%.%6%7%A%B%N%O%Z%t%‚%Œ%”%—%˘%Ł%Ť%Ź%´%š%É%î%ř%ů%&&&&&M&[&^&i&l&y&Ż&˝&ż&Ĺ&6'D'†''Ł'­'((@(I(T(b(c(k(s((‚(Ÿ(Ň(ŕ(â(č(é(ń())) )D)R)™)˘)˝)Č)**X*e*‡*’*Ł*˛*É*Ň*b+n+ô+ü+,,X,a,o,x,é,ň, --9-A-X-_-p.y.Ý.ß.ú.ü.D/M/ą/ł/Î/Đ/0!0‹00Ť0­0ü0ţ0`1f1j1t1y11ä1ď122;2E2O2d2k2 333%3)3133˜3á3é3/474{4ƒ4Ď4Ü4Ý4ä4š5§5¨5Ż5Ä5Ň56646A6B6H6U6_6`6q6z6†6‹6–6Ž6ş6ç6đ6i7s738>8B8M8N8V8W8`8{8ˆ8‰88˘8Ź8Ĺ8Ń849?9C9J9\9e9o9{9‡9™9Ŕ9Í9Ň9Ü9Ţ9ĺ9ć9ë9B:H:“:–:Ü:ß: ; ;>;A;g;n;ˆ;•;;Š;Ž;¸;ź;Ě;Đ;Ü;â;ć;<$<(<4<C<P<_<i<j<q<­<ł<ˇ<Ă<Đ<Ř<î<ř<ů<=/=5===H=L=X=\=h=l=|=Ź=´=Đ=â=ç=ď= >>V>^>‹>“>Ě>Ô>ő>?)?4?\?g?‘?œ?é?ń?@@E@P@_@l@}@ˆ@—@¤@´@ż@Î@Ű@ń@ú@!A*ALAUAfAoA•A˜A™A›AœAĄAÜAĺABBuB~BƒBBC%C?CKCžCÉCäCóCaDlDçDîD4EJGJ—JJľJÁJÂJÇJČJĚJŃJ×JíJúJƒK‹K$L0L>LMLL•LĎLÜLéLęLMM%M'M=M>MÇMÍM¸NžNőNOOO.O6O[OfO“O™OśOÁOÇOĎOÓOŢOâOęOP!P#P/P3PtFtatitktpt}t‹tűtuPu^uÚuäu˙uvvžvŸvŹv­všvw w!w&w(w/w4wCwUw]wcwqwćwńw4x>xOx\x^xlxpx~x€x‹xx•xżxÍxŃxŰx+y2yRyYyÂyĹyČyŐyÝyŕyëyůyzzzz'z7ŒIŒŽÍ1Í">Jh o ľ ź Í Ó úüY[BCňűŻş`eŠ˛S [ =#A#Ż&˝&ń'ó'@(I(Ň(ŕ(Ń)×)›*Ą*+%+Ň+ă+T,a,ĺ,ň, 1&1j1u1ď3ń3‰4‹4ľ4¸466Ä6Ç6Ń7Ű788N8V8W8`8f9m9};‡;=„=”>™>č>đ>@ @˙@A0A5ALAUAqA{AB&B'B0BoBtBôCDKDYDÂDÇD…EEüEFČJĚJ-K6KNL\LoL{LĆMÍMˇNžN’O™OP PP!P#P/PiPmPaSjSáSčSŰTâTNVZVtV|VŒV˜VÍVŘVWW“W–WűZ[M[T[Ç[Ö["^)^N_Z_é_ě_pauaţab‘e“e4hŚ>0A˘AüA1BŹCôC$L|LPMP‘RÄRASaS’S­S°UVNVŒVXWWÚW^XŤ[ă[Ŕ]^î^._e3eylÓl‚mŽmu}ô}o~ś~Sˇĺđ(‚“‚ŸƒÄƒŽ‘î‘‚’“r“¤“Ó”•E•S•ş— ˜¤˜ ™ŢžšĘđĚ.Í1ÍtOhF˛ }˙˙˙˙˙˙˙˙˙ Ö˜J˙˙˙˙˙˙˙˙˙Xâž3Ęö˙˙˙˙˙˙˙˙˙đx˛Žböß˙˙˙˙˙˙˙˙˙/<–ęň˙˙˙˙˙˙˙˙˙JVŔ.ŮfŮ˙˙˙˙˙˙˙˙˙a" w”ş˙˙˙˙˙˙˙˙˙r&Ť4‡2˙˙˙˙˙˙˙˙˙TQ źş˜˙˙˙˙˙˙˙˙˙Ĺy9 ˆÓÔ´˙˙˙˙˙˙˙˙˙SŒ ř–|˙˙˙˙˙˙˙˙˙ Ęô¤B˙˙˙˙˙˙˙˙˙Ăş œşO˙˙˙˙˙˙˙˙˙zk-†HŽŻ˙˙˙˙˙˙˙˙˙ďQc’s&S˙˙˙˙˙˙˙˙˙Q ÎŹ™˙˙˙˙˙˙˙˙˙˛c˘Ô˜Ÿ˙˙˙˙˙˙˙˙˙ězn§’â˙˙˙˙˙˙˙˙˙řPŽ’ć˙˙˙˙˙˙˙˙˙7OҸşd˙˙˙˙˙˙˙˙˙×,>–l˙˙˙˙˙˙˙˙˙6Č˙˙˙˙˙˙˙˙˙w}*¨6Î˙˙˙˙˙˙˙˙˙ifádev˙˙˙˙˙˙˙˙˙äS7|H4H˙˙˙˙˙˙˙˙˙ŇcyZř”˙˙˙˙˙˙˙˙˙ {ń€}ž}˙˙˙˙˙˙˙˙˙nINVóPĄ˙˙˙˙˙˙˙˙˙ až´ŘJ ˙˙˙˙˙˙˙˙˙œrk’ŒŘľ˙˙˙˙˙˙˙˙˙‡FŘ°a.ď˙˙˙˙˙˙˙˙˙{*j0x¤ą˙˙˙˙˙˙˙˙˙laOhĂb˙˙˙˙˙˙˙˙˙Ę6_ŢD>W˙˙˙˙˙˙˙˙˙z Âţ đN˙˙˙˙˙˙˙˙˙F{!|NĚ˙˙˙˙˙˙˙˙˙ˇ P"RmNt˙˙˙˙˙˙˙˙˙,¸#€`FQ˙˙˙˙˙˙˙˙˙ü_=%Pš†‡˙˙˙˙˙˙˙˙˙ď]˘&ŒĎŞá˙˙˙˙˙˙˙˙˙DBĄ)|)Œ6˙˙˙˙˙˙˙˙˙ź+ą)RÓt˙˙˙˙˙˙˙˙˙ŕ*4Qź˙˙˙˙˙˙˙˙˙óvĽ0°ętS˙˙˙˙˙˙˙˙˙—YL2$™ň—˙˙˙˙˙˙˙˙˙űq#3:řřĺ˙˙˙˙˙˙˙˙˙M$g3°Ź§˙˙˙˙˙˙˙˙˙ĂYp5b!ň“˙˙˙˙˙˙˙˙˙?Hĺ5L‰RĐ˙˙˙˙˙˙˙˙˙ĄUg6€=‚Š˙˙˙˙˙˙˙˙˙ rs7fş ˙˙˙˙˙˙˙˙˙‰o8Búfl˙˙˙˙˙˙˙˙˙q59Ž˛s˙˙˙˙˙˙˙˙˙$;A9h˛”˙˙˙˙˙˙˙˙˙Ç9Šf˙˙˙˙˙˙˙˙˙˙@=V JŹ˙˙˙˙˙˙˙˙˙éKm=äŽĘ˙˙˙˙˙˙˙˙˙[cČ=jnĐ˙˙˙˙˙˙˙˙˙3Kš>n„ i˙˙˙˙˙˙˙˙˙ď˝>€Fż˙˙˙˙˙˙˙˙˙ô3@>ć˙˙˙˙˙˙˙˙˙ĘużAĐE˙˙˙˙˙˙˙˙˙9%“C–cjq˙˙˙˙˙˙˙˙˙`DP×^˙˙˙˙˙˙˙˙˙ˆ4IEÂŮ~ű˙˙˙˙˙˙˙˙˙ŐacG(„b˙˙˙˙˙˙˙˙˙Ą:ĽGôç˙˙˙˙˙˙˙˙˙N0RHVWlČ˙˙˙˙˙˙˙˙˙YbH€¸Č˙˙˙˙˙˙˙˙˙E+°IŞirX˙˙˙˙˙˙˙˙˙óK˘Kœoúű˙˙˙˙˙˙˙˙˙úLz—Ś%˙˙˙˙˙˙˙˙˙n{M(k’˙˙˙˙˙˙˙˙˙ůcsNđLč˙˙˙˙˙˙˙˙˙“|Oj:¸Ć˙˙˙˙˙˙˙˙˙ śPôš„0˙˙˙˙˙˙˙˙˙f nRüĆöĄ˙˙˙˙˙˙˙˙˙XS˜°q˙˙˙˙˙˙˙˙˙Źy&Tě3îú˙˙˙˙˙˙˙˙˙¸užT¸_HÉ˙˙˙˙˙˙˙˙˙^+ŸTĐ4Ó˙˙˙˙˙˙˙˙˙' œUę:Ś÷˙˙˙˙˙˙˙˙˙îIVČ˙h˙˙˙˙˙˙˙˙˙m¸W P˙˙˙˙˙˙˙˙˙f_Xźľčŕ˙˙˙˙˙˙˙˙˙–#ŰX&_4ś˙˙˙˙˙˙˙˙˙ă-[{~’˙˙˙˙˙˙˙˙˙€{ń[ŽGtI˙˙˙˙˙˙˙˙˙FCĆ]B…˙˙˙˙˙˙˙˙˙˙ ^˘ ä˙˙˙˙˙˙˙˙˙Ëki`ěĄÜ"˙˙˙˙˙˙˙˙˙řz­ažFĐG˙˙˙˙˙˙˙˙˙8Űb–^äü˙˙˙˙˙˙˙˙˙nG_e>†.˙˙˙˙˙˙˙˙˙FigeżĘä˙˙˙˙˙˙˙˙˙].˜iH ç˙˙˙˙˙˙˙˙˙ß.pmöĚި˙˙˙˙˙˙˙˙˙ű%Vn`& ˙˙˙˙˙˙˙˙˙laoÂč>ß˙˙˙˙˙˙˙˙˙*ŐoFaĐŰ˙˙˙˙˙˙˙˙˙÷JFqśĺˆP˙˙˙˙˙˙˙˙˙ţr0NŔ˙˙˙˙˙˙˙˙˙ “ttց˙˙˙˙˙˙˙˙˙‹T°t”5*_˙˙˙˙˙˙˙˙˙ÄuwśŔ‰˙˙˙˙˙˙˙˙˙Âo‹w~°m˙˙˙˙˙˙˙˙˙”AśxäĚ2˙˙˙˙˙˙˙˙˙Qőzd]ş˙˙˙˙˙˙˙˙˙{´P*Đ˙˙˙˙˙˙˙˙˙BVď{Ţř|Ă˙˙˙˙˙˙˙˙˙Q7E|l†—˙˙˙˙˙˙˙˙˙Ŕ:t|:2š#˙˙˙˙˙˙˙˙˙5[Ł|ŕˇř„˙˙˙˙˙˙˙˙˙'˙|j‹˙˙˙˙˙˙˙˙˙&,ˇ}ĘĽB ˙˙˙˙˙˙˙˙˙žOԐUč^˙˙˙˙˙˙˙˙˙h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „8„˜ţĆ8^„8`„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „Ř „L˙ĆŘ ^„Ř `„L˙‡hˆH.h „¨ „˜ţƨ ^„¨ `„˜ţ‡hˆH.h „x„˜ţĆx^„x`„˜ţ‡hˆH.’h „H„L˙ĆH^„H`„L˙‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.h „č„˜ţĆč^„č`„˜ţ‡hˆH.’h „¸„L˙Ƹ^„¸`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţCJo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „8„˜ţĆ8^„8`„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „Ř „L˙ĆŘ ^„Ř `„L˙‡hˆH.h „¨ „˜ţƨ ^„¨ `„˜ţ‡hˆH.h „x„˜ţĆx^„x`„˜ţ‡hˆH.’h „H„L˙ĆH^„H`„L˙‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.h „č„˜ţĆč^„č`„˜ţ‡hˆH.’h „¸„L˙Ƹ^„¸`„L˙‡hˆH.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „„„˜ţĆ„^„„`„˜ţ‡hˆH.h „T„˜ţĆT^„T`„˜ţ‡hˆH.’h „$ „L˙Ć$ ^„$ `„L˙‡hˆH.h „ô „˜ţĆô ^„ô `„˜ţ‡hˆH.h „Ä„˜ţĆÄ^„Ä`„˜ţ‡hˆH.’h „”„L˙Ć”^„”`„L˙‡hˆH.h „d„˜ţĆd^„d`„˜ţ‡hˆH.h „4„˜ţĆ4^„4`„˜ţ‡hˆH.’h „„L˙Ć^„`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţ5o(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.x „ŕ„˜ţĆŕ^„ŕ`„˜ţo(‡hˆH.x „ „˜ţ^„ `„˜ţ‡hˆH.’x „p„L˙^„p`„L˙‡hˆH.x „@ „˜ţ^„@ `„˜ţ‡hˆH.x „„˜ţ^„`„˜ţ‡hˆH.’x „ŕ„L˙^„ŕ`„L˙‡hˆH.x „°„˜ţ^„°`„˜ţ‡hˆH.x „€„˜ţ^„€`„˜ţ‡hˆH.’x „P„L˙^„P`„L˙‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.h „Ü„˜ţĆÜ^„Ü`„˜ţ‡hˆH.’h „Ź„L˙ĆŹ^„Ź`„L˙‡hˆH.h „| „˜ţĆ| ^„| `„˜ţ‡hˆH.h „L„˜ţĆL^„L`„˜ţ‡hˆH.’h „„L˙Ć^„`„L˙‡hˆH.h „ě„˜ţĆě^„ě`„˜ţ‡hˆH.h „ź„˜ţĆź^„ź`„˜ţ‡hˆH.’h „Œ„L˙ĆŒ^„Œ`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH.h „h„˜ţĆh^„h`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.x „X„˜ţĆX^„X`„˜ţo(‡hˆH.x „„˜ţ^„`„˜ţ‡hˆH.’x „č„L˙^„č`„L˙‡hˆH.x „¸ „˜ţ^„¸ `„˜ţ‡hˆH.x „ˆ„˜ţ^„ˆ`„˜ţ‡hˆH.’x „X„L˙^„X`„L˙‡hˆH.x „(„˜ţ^„(`„˜ţ‡hˆH.x „ř„˜ţ^„ř`„˜ţ‡hˆH.’x „Č„L˙^„Č`„L˙‡hˆH.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH.h „p„˜ţĆp^„p`„˜ţ‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.’h „„L˙Ć^„`„L˙‡hˆH.h „ŕ„˜ţĆŕ^„ŕ`„˜ţ‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.’h „€„L˙Ć€^„€`„L˙‡hˆH.h „P„˜ţĆP^„P`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „đ„L˙Ćđ^„đ`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.„ „˜ţĆ ^„ `„˜ţo(.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH. „Đ„˜ţĆĐ^„Đ`„˜ţ56o(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH. „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.€ „ „˜ţĆ ^„ `„˜ţ‡hˆH.‚ „p„L˙Ćp^„p`„L˙‡hˆH.€ „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.€ „„˜ţĆ^„`„˜ţ‡hˆH.‚ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.€ „°„˜ţĆ°^„°`„˜ţ‡hˆH.€ „€„˜ţĆ€^„€`„˜ţ‡hˆH.‚ „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.h „Ü„˜ţĆÜ^„Ü`„˜ţ‡hˆH.’h „Ź„L˙ĆŹ^„Ź`„L˙‡hˆH.h „| „˜ţĆ| ^„| `„˜ţ‡hˆH.h „L„˜ţĆL^„L`„˜ţ‡hˆH.’h „„L˙Ć^„`„L˙‡hˆH.h „ě„˜ţĆě^„ě`„˜ţ‡hˆH.h „ź„˜ţĆź^„ź`„˜ţ‡hˆH.’h „Œ„L˙ĆŒ^„Œ`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.h „Ü„˜ţĆÜ^„Ü`„˜ţ‡hˆH.’h „Ź„L˙ĆŹ^„Ź`„L˙‡hˆH.h „| „˜ţĆ| ^„| `„˜ţ‡hˆH.h „L„˜ţĆL^„L`„˜ţ‡hˆH.’h „„L˙Ć^„`„L˙‡hˆH.h „ě„˜ţĆě^„ě`„˜ţ‡hˆH.h „ź„˜ţĆź^„ź`„˜ţ‡hˆH.’h „Œ„L˙ĆŒ^„Œ`„L˙‡hˆH.h „8„˜ţĆ8^„8`„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „Ř „L˙ĆŘ ^„Ř `„L˙‡hˆH.h „¨ „˜ţƨ ^„¨ `„˜ţ‡hˆH.h „x„˜ţĆx^„x`„˜ţ‡hˆH.’h „H„L˙ĆH^„H`„L˙‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.h „č„˜ţĆč^„č`„˜ţ‡hˆH.’h „¸„L˙Ƹ^„¸`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH.h „„„˜ţĆ„^„„`„˜ţ‡hˆH.h „T„˜ţĆT^„T`„˜ţ‡hˆH.’h „$ „L˙Ć$ ^„$ `„L˙‡hˆH.h „ô „˜ţĆô ^„ô `„˜ţ‡hˆH.h „Ä„˜ţĆÄ^„Ä`„˜ţ‡hˆH.’h „”„L˙Ć”^„”`„L˙‡hˆH.h „d„˜ţĆd^„d`„˜ţ‡hˆH.h „4„˜ţĆ4^„4`„˜ţ‡hˆH.’h „„L˙Ć^„`„L˙‡hˆH.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH. „Đ„˜ţĆĐ^„Đ`„˜ţ>*CJo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „8„˜ţĆ8^„8`„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „Ř „L˙ĆŘ ^„Ř `„L˙‡hˆH.h „¨ „˜ţƨ ^„¨ `„˜ţ‡hˆH.h „x„˜ţĆx^„x`„˜ţ‡hˆH.’h „H„L˙ĆH^„H`„L˙‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.h „č„˜ţĆč^„č`„˜ţ‡hˆH.’h „¸„L˙Ƹ^„¸`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH. „„Ć^„`„o(‡hˆH. „ „˜ţĆ ^„ `„˜ţ‡hˆH.’ „p„L˙Ćp^„p`„L˙‡hˆH. „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH. „„˜ţĆ^„`„˜ţ‡hˆH.’ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH. „°„˜ţĆ°^„°`„˜ţ‡hˆH. „€„˜ţĆ€^„€`„˜ţ‡hˆH.’ „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţ^„Đ`„˜ţ‡hˆH.h „ „˜ţ^„ `„˜ţ‡hˆH.’h „p„L˙^„p`„L˙‡hˆH.h „@ „˜ţ^„@ `„˜ţ‡hˆH.h „„˜ţ^„`„˜ţ‡hˆH.’h „ŕ„L˙^„ŕ`„L˙‡hˆH.h „°„˜ţ^„°`„˜ţ‡hˆH.h „€„˜ţ^„€`„˜ţ‡hˆH.’h „P„L˙^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH. „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.€ „ „˜ţĆ ^„ `„˜ţ‡hˆH.‚ „p„L˙Ćp^„p`„L˙‡hˆH.€ „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.€ „„˜ţĆ^„`„˜ţ‡hˆH.‚ „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.€ „°„˜ţĆ°^„°`„˜ţ‡hˆH.€ „€„˜ţĆ€^„€`„˜ţ‡hˆH.‚ „P„L˙ĆP^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţo(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.h „ŕ„˜ţ^„ŕ`„˜ţo(‡hˆH.€ „°„˜ţ^„°`„˜ţ‡hˆH.‚ „€„L˙^„€`„L˙‡hˆH.€ „P „˜ţ^„P `„˜ţ‡hˆH.€ „ „˜ţ^„ `„˜ţ‡hˆH.‚ „đ„L˙^„đ`„L˙‡hˆH.€ „Ŕ„˜ţ^„Ŕ`„˜ţ‡hˆH.€ „„˜ţ^„`„˜ţ‡hˆH.‚ „`„L˙^„``„L˙‡hˆH.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.„Đ„˜ţĆĐ^„Đ`„˜ţ5o(.€„ „˜ţĆ ^„ `„˜ţ.‚„p„L˙Ćp^„p`„L˙.€„@ „˜ţĆ@ ^„@ `„˜ţ.€„„˜ţĆ^„`„˜ţ.‚„ŕ„L˙Ćŕ^„ŕ`„L˙.€„°„˜ţĆ°^„°`„˜ţ.€„€„˜ţĆ€^„€`„˜ţ.‚„P„L˙ĆP^„P`„L˙.h „Đ„˜ţĆĐ^„Đ`„˜ţ‡hˆH.h „ „˜ţĆ ^„ `„˜ţ‡hˆH.’h „p„L˙Ćp^„p`„L˙‡hˆH.h „@ „˜ţĆ@ ^„@ `„˜ţ‡hˆH.h „„˜ţĆ^„`„˜ţ‡hˆH.’h „ŕ„L˙Ćŕ^„ŕ`„L˙‡hˆH.h „°„˜ţĆ°^„°`„˜ţ‡hˆH.h „€„˜ţĆ€^„€`„˜ţ‡hˆH.’h „P„L˙ĆP^„P`„L˙‡hˆH.uź+ą)Ňcy/<BVď{ifá¸užTFige' œU“|Oŕ*{ězß.pmOh'˙|Q7E| “tĂş Pň 0‡FŘw}*ď]˘&úLîIVm¸WĄ:ĽGXSM$g3Âo‹wţrďQczk-ă-[žOÔ{*j9%“ClaOäS7n{MĹy9 ,¸#ô3@œrkűq#3 XâĘ6_ śPůcsNN0RHf nRřP`D8ŰbŹy&TQőz7OŇÇ9 až”AśxSŒ nG_eđx˛÷JFqŔ:t|ď˝>?Hĺ5řz­aDBĄ)JVŔ {ńű%Vn$;A9Q&,ˇ}Ŕ#ă 0ˇ P"ĄUg6řz­a$ă 0Äuw`$ă 0E+°I°$ă 0r&Ť%ă 0f_XP%ă 0q59 %ă 0óvĽ0].˜i˙ ^Ëki`@= rs7TQ ×z  lao^+ŸTéKm=‹T°tü_=%‰o8a"5[Ł|YbH€{ń[˛c˘ĘużA[cČ=RĚđ%ă 0ŐacGüQĚ@&ă 0FCĆ]řO̐&ă 0—YL2ôOĚŕ&ă 0F{!đOĚ0'ă 0–#ŰXěÒ'ă 0*ŐoRĚĐ'ă 03Kš>RĚ (ă 0nINR̀Üí 0ĂYp5RĚĐÜí 0ˆ4IE RĚ Ýí 0óK˘KRĚpÝí 0˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙Œ0˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙0ąŒ0ąą  @Œ0ÄŁ|¨(ŠŞŒ0`°Œ0űŞąŤîŹŻ˙˙w˙˙w         &h\H                           Źg(E         Źg(E \&Y         Źg(EŹg(EŹg(E                                    Źg(EŹg(EŹg(EŹg(E ŚT—       Źg(E         Źg(EęZ.ľ         Źg(EŹg(EŹg(EęZ.ľţŽ Źg(E         Źg(E                  ĺ—ZžJ ÷/Í1Í˙@Đ .01éLéMéSéTéUéWéXL˘LŁLĂ/̀@€&€(€T@€8€<€|@€Z€¸@€b€d€Ě@€h€Ô@€´€l@€p@˙˙Unknown˙˙˙˙˙˙˙˙˙˙˙˙GĚ‡* €˙Times New Roman5€Symbol3.Ě ‡* €˙ArialI.€ ˙Ż˙÷˙˙ßé?˙?Arial Unicode MS?=Ě ‡* €˙Courier New7Ěď K@ŸCambria7.Ěď { @ŸCalibriACambria Math"0ˆđÄh$8ĺŚ`[ĺF=ŸŽhtŸŽht!đĐƒ´´0dÇĚÇĚ 2ƒqđÜ˙˙HX đ˙$Pă˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙—Zž2u!xx ˙˙ Asthma (I)AlexYour User NameÜt                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s ţ˙ŕ…ŸňůOhŤ‘+'łŮ0x˜Ź¸ČÔŕđ  4 @ LX`hpă Asthma (I)AlexNormalYour User Name22Microsoft Office Word@Ž‡…@ ŁdíĘ@P60őđĘŸŽţ˙ŐÍ՜.“—+,ůŽDŐÍ՜.“—+,ůŽ<ř hp€ˆ˜  ¨°¸ Ŕ ×ăHomethÇĚ  Asthma (I)  Íŕçâŕíčĺ 8@ _PID_HLINKSăAČ4f'http://en.wikipedia.org/wiki/DysphagiaYM6http://emedicine.medscape.com/article/201066-overview^M6http://emedicine.medscape.com/article/175667-overview  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€‚ƒ„…†‡ˆ‰Š‹ŒŽ‘’“”•–—˜™š›œžŸ Ą˘Ł¤ĽŚ§¨ŠŞŤŹ­ŽŻ°ą˛ł´ľśˇ¸šşťź˝žżŔÁÂĂÄĹĆÇČÉĘËĚÍÎĎĐŃŇÓÔŐÖ×ŘŮÚŰÜÝŢßŕáâăäĺćçţ˙˙˙éęëěíîďđńňóôőö÷řůúűüýţ˙      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€‚ƒ„…†‡ˆ‰Š‹ŒŽ‘’“”•–—˜™š›œžŸ Ą˘Ł¤ĽŚ§¨Šţ˙˙˙ŤŹ­ŽŻ°ąţ˙˙˙ł´ľśˇ¸šţ˙˙˙ý˙˙˙ý˙˙˙ý˙˙˙ý˙˙˙żţ˙˙˙ţ˙˙˙ţ˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙Root Entry˙˙˙˙˙˙˙˙ ŔF§÷MőđĘÁ€1Table˙˙˙˙˙˙˙˙范WordDocument˙˙˙˙˙˙˙˙.ÎSummaryInformation(˙˙˙˙ŞDocumentSummaryInformation8˙˙˙˙˙˙˙˙˙˙˙˙˛CompObj˙˙˙˙˙˙˙˙˙˙˙˙y˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙ţ˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙ţ˙ ˙˙˙˙ ŔF'Äîęóěĺíň Microsoft Office Word 97-2003 MSWordDocWord.Document.8ô9˛q